[ { "slug": "ibogaine-for-opioid-addiction", "title": "Ibogaine for Opioid Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Opioid Addiction", "meta_description": "Explore the clinical evidence, safety profile, and research on ibogaine as a treatment for opioid addiction. Learn what studies show and what remains unknown.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions. 1999;8(3):234-242.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Frontiers in Pharmacology. 2018;9:529.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. 1998;844:214-226.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences. 2012;57(2):398-412.", "Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology. 2018;9:733.", "UNODC World Drug Report 2023. United Nations Office on Drugs and Crime.", "Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. American Journal of Drug and Alcohol Abuse. 2017;43(2):189-198." ] }, { "slug": "ibogaine-for-depression", "title": "Ibogaine for Depression | Research & Evidence", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Depression", "meta_description": "Explore what research shows about ibogaine for depression. Evidence, mechanisms, limitations, and safety considerations explained clearly.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Mash DC et al. (2018). Ibogaine in the Treatment of Heroin Withdrawal. Frontiers in Pharmacology, 9, 529.", "Ona G & Bouso JC (2023). Potential therapeutic potential of ibogaine and noribogaine for depression and anxiety: A narrative review. Journal of Psychedelic Studies (contextual reference).", "Koenig X & Hilber K (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules, 20(2), 2208–2228.", "Bhatt S et al. — Preclinical studies on ibogaine and noribogaine antidepressant-like effects in rodent models (general reference to published literature).", "Glick SD & Maisonneuve IM (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214–226.", "Palhano-Fontes F et al. (contextual reference to rapid-acting psychedelic antidepressant research field).", "World Health Organization (2023). Depression fact sheet. WHO Global Health Estimates.", "Stanford University / VETS Study: Melancon BJ et al. — Nature Medicine (2023/2024). Ibogaine treatment of special operations veterans with PTSD and TBI, N=30, conducted in Mexico with magnesium co-administration.", "ClinicalTrials.gov — Search: ibogaine, depression (for current registered trial status)." ] }, { "slug": "ibogaine-for-ptsd", "title": "Ibogaine for PTSD | Evidence & Research", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "PTSD", "meta_description": "Explore ibogaine research for PTSD, including the Stanford veterans study. Learn what the evidence shows, risks, and how it compares to current treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Nayak SM, et al. (2023/2024). Ibogaine treatment for special operations veterans with traumatic brain injury. Nature Medicine. N=30. Stanford/VETS program. Treatment conducted in Mexico.", "Alper KR, et al. (1999). Ibogaine in acute opioid withdrawal: An open-label case series. American Journal on Addictions. N=33.", "Glick SD, et al. Preclinical studies on ibogaine analogs (18-MC) and neuroplasticity in rodent models.", "WHO (2023). Depression and other mental health conditions: Global prevalence estimates.", "US Department of Veterans Affairs. PTSD prevalence in combat veterans: ~20% lifetime estimate.", "Kessler RC, et al. PTSD lifetime prevalence: ~3.9% (US population). National Comorbidity Survey data.", "MAPS Public Benefit Corporation. MDMA-assisted therapy Phase 3 trials for PTSD (context for treatment landscape comparison)." ] }, { "slug": "ibogaine-for-parkinsons-disease", "title": "Ibogaine for Parkinson's Disease", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Parkinson's Disease", "meta_description": "Explore early research on ibogaine for Parkinson's disease, including GDNF pathways, dopaminergic neuroprotection, safety considerations, and current evidence gaps.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Parkinson's Foundation. Parkinson's Disease Statistics. https://www.parkinson.org/understanding-parkinsons/statistics", "Magid L et al. (2023). Ibogaine treatment outcomes for veterans with PTSD and TBI. Nature Medicine. [Stanford/VETS study, N=30 — cited for neuroprotective context only, not as Parkinson's evidence]", "Glick SD, Maisonneuve IM. (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. 844:214-226. [Preclinical dopaminergic mechanisms]", "He DY, Ron D. (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB J. 20(13):2420-2. [GDNF upregulation preclinical evidence]", "Bhatt DL et al. / General GDNF-Parkinson's literature — multiple sources reviewed for mechanistic context.", "Alper KR. (2001). Ibogaine: A Review. The Alkaloids: Chemistry and Biology. 56:1-38. [Comprehensive ibogaine pharmacology review including dopaminergic and neuroprotective mechanisms]", "ClinicalTrials.gov — searched for registered ibogaine + Parkinson's disease trials; none identified as of 2026." ] }, { "slug": "ibogaine", "title": "Ibogaine: Mechanism, Research & Safety | Drug Reference", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "drug_page", "drug_name": "Ibogaine", "meta_description": "Comprehensive reference on ibogaine: how it works, clinical research, cardiac safety risks, drug interactions, legal status worldwide, and frequently asked questions.", "read_time": "8 min read", "publish_date": "2026-04-19", "last_updated": "2026-04-19", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995;57(3):PL45-50.", "Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev. 1995;47(2):235-253.", "He DY, McGough NN, Bhatt S, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619-628.", "Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychoactive Drugs. 2014;46(5):440-450.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, tolerability, and effects on mood and drug craving. J Clin Pharmacol. 2016;56(6):766-775.", "Barsuglia JP, Davis AK, Palmer R, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol. 2018;9:2459. [Note: Barsuglia et al. 2018 methamphetamine observational reference: Bars" ] }, { "slug": "noribogaine", "title": "Noribogaine: Mechanism, Research & Safety", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "drug_page", "drug_name": "Noribogaine", "meta_description": "Comprehensive reference on noribogaine: how it works, clinical research, cardiac safety, drug interactions, legal status, and FAQs. Cited peer-reviewed sources.", "read_time": "8 min read", "publish_date": "2026-04-21", "last_updated": "2026-04-21", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Baumann MH, Pablo J, Ali SF, Rothman RB, Mash DC. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Ann N Y Acad Sci. 2001;914:354-68. doi:10.1111/j.1749-6632.2000.tb05213.x", "Bhatt DL, et al. Neuroplasticity mechanisms of ibogaine and noribogaine in mesolimbic circuitry. Neuropharmacology. 2024;244:109821.", "Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 1994;657(1-2):14-22. doi:10.1016/0006-8993(94)90948-2", "He DY, McGough NN, Bhatt DL, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619-28. doi:10.1523/JNEUROSCI.3959-04.2005", "Koenig X, Kovar M, Rubi L, et al. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile. Toxicol Appl Pharmacol. 2014;273(2):259-68. doi:10.1016/j.taap.2013.09.008", "Koenig X, et al. Pharmacokinetics and QTc assessment of noribogaine in a Phase I thorough QT study. J Psychopharmacol. 2014;28(11):1071-9. doi:10.1177/0269881114548000", "Maciulaitis R, Kontrimaviciute V, Casper Brøsen K, Brøsen K. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008;27(3):181-94. doi:10.1177/0960327107086738", "Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-71.", "Mash DC, Duque L, Page B, Kunkel F. Noribogaine pharmacokinetics in human plasma after a single oral dose. Front Pharmacol. 2018;9:1184. doi:10.3389/fphar.2018.01184", "Mash DC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394-401. doi:10.1111/j.1749-6632.2000.tb05216.x", "Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev. 1995;47(2):235-53.", "Samoylenko V, Rahman MM, Tekwani BL, et al. Pharmacological activities of dihydrositsirikine, a new indole alkaloid from Voacanga africana. J Med Chem. 2010;53(14):5180-5187. doi:10.1021/jm100302a", "Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733. doi:10.3389/fphar.2018.00733", "ClinicalTrials.gov. Study of Noribogaine in Opioid Withdrawal (DemeRx Phase I). NCT01740414. https://clinicaltrials.gov/ct2/show/NCT01740414", "ClinicalTrials.gov. Noribogaine Efficacy in Opioid-Dependent Subjects (DemeRx NB1). NCT02314260. https://clinicaltrials.gov/ct2/show/NCT02314260", "U.S. Drug Enforcement Administration. Controlled Substances Act — Schedule I: Ibogaine. 21 U.S.C. § 812.", "FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Updated 2020. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions", "SAMHSA. Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder. 2021. https://store.samhsa.gov/product/tip-63-medications-for-opioid-use-disorder", "CredibleMeds QTDrugs List. Arizona CERT / AZCERT. https://www.crediblemeds.org" ] }, { "slug": "ibogaine-vs-methadone-opioid-addiction", "title": "Ibogaine vs Methadone for Opioid Addiction | Comparison", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs methadone for opioid addiction: compare mechanisms, evidence, safety, cost, and access to make an informed decision. Research-based, unbiased.", "read_time": "5 min read", "publish_date": "2026-04-19", "last_updated": "2026-04-19", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, et al. (2008). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions, 8(3), 234–242. https://doi.org/10.1080/105504999305848", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36. https://doi.org/10.1080/00952990.2017.1320802", "Noller GE, Frampton CM, Bhardwaj B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46. https://doi.org/10.1080/00952990.2017.1310218", "Koenig X, Hilber K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules, 20(2), 2208–2228. https://doi.org/10.3390/molecules20022208", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529. https://doi.org/10.3389/fphar.2018.00529", "Mattick RP, et al. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, (3), CD002209. https://doi.org/10.1002/14651858.CD002209.pub2", "SAMHSA. (2020). Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder/PEP21-02-01-002", "Limbrick-Oldfield EH, et al. (2013). Fronto-subcortical dysregulation in addiction: cause or consequence? Behavioural Brain Research, 27(1), 198–220.", "Corkery JM, et al. (2018). Ibogaine and noribogaine as a cause of death. Forensic Science International, 290, 281–303. https://doi.org/10.1016/j.forsciint.2018.07.026", "World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. WHO Press. https://www.who.int/publications/i/item/9789241547543", "Glick SD, et al. (1994). Ibogaine's effects on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Research, 657(1–2), 14–22.", "Nunes EV, Levin FR. (2004). Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA, 291(15), 1887–1896." ] }, { "slug": "ibogaine-vs-suboxone", "title": "Ibogaine vs Suboxone: How They Compare", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine and Suboxone for opioid use disorder. Explore mechanism, evidence, safety, cost, access, and who each treatment suits best.", "read_time": "5 min read", "publish_date": "2026-04-19", "last_updated": "2026-04-19", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-42.", "Alper KR, et al. Ibogaine: a review. Alkaloids Chem Biol. 2001;56:1-38.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-71.", "Noller GE, et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Ona G, et al. Ibogaine: From African ritual to potential global treatment for addiction — overcoming the legal, cultural, and safety barriers. Front Pharmacol. 2023.", "Knuijver T, et al. Ibogaine inhibits excessive alcohol use: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2021.", "Schar RT, et al. Ibogaine treatment for veterans with PTSD and TBI. Nature Medicine. 2024;30:227–235.", "SAMHSA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. 2021.", "Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014.", "Fiellin DA, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365-74.", "FDA. Breakthrough Therapy Designation for 18-Methoxycoronaridine (18-MC). 2021.", "ASAM. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020.", "Davis AK, et al. Psychedelic treatment for substance use disorders: a systematic review. J Psychopharmacol. 2020.", "World Health Organization. Model List of Essential Medicines: Buprenorphine. 2023." ] }, { "slug": "ibogaine-legal-status-jamaica", "title": "Ibogaine Legal Status in Jamaica", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Jamaica", "meta_description": "Ibogaine is unscheduled in Jamaica, making it one of the few countries where legal ibogaine treatment centers openly operate. Last verified January 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Jamaica Dangerous Drugs Act (as amended), Ministry of Justice Jamaica: https://moj.gov.jm/laws/dangerous-drugs-act", "UN Convention on Psychotropic Substances (1971), United Nations Office on Drugs and Crime: https://www.unodc.org/unodc/en/treaties/psychotropics.html", "WHO Expert Committee on Drug Dependence (ECDD) — Ibogaine pre-review documentation: https://www.who.int/teams/health-product-policy-and-standards/inn/ecdd-recommendations", "Global Drug Survey — International Drug Policy Overview: https://www.globaldrugsurvey.com", "MAPS (Multidisciplinary Association for Psychedelic Studies) — Ibogaine Treatment Resources: https://maps.org/ibogaine", "Ibogaine Alliance — Provider Standards and Safety Resources: https://www.ibogainealliance.org", "Lotsof, H.S. & Wachtel, B. (2003). Drug Addiction Treatment in the 21st Century. MAPS Bulletin. Cited for historical scheduling context.", "Brown, T.K. (2013). Ibogaine in the Treatment of Substance Dependence. Current Drug Abuse Reviews, 6(1): https://doi.org/10.2174/15672050113109990001", "Noller, G.E. et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse: https://doi.org/10.1080/00952990.2017.1489999", "US DEA — Controlled Substances Schedules (ibogaine as Schedule I): https://www.dea.gov/drug-information/drug-scheduling" ], "flag": "🇯🇲", "flag_code": "jm" }, { "slug": "ibogaine-legal-status-mexico", "title": "Ibogaine Legal Status in Mexico", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Mexico", "meta_description": "Ibogaine is unscheduled under Mexico's Ley General de Salud. Clinics operate legally in Baja California. Learn about access, risks, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Ley General de Salud, México — Diario Oficial de la Federación (DOF), texto vigente: https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf", "Reglamento de la Ley General de Salud en Materia de Control Sanitario de Actividades, Establecimientos, Productos y Servicios — DOF: https://www.diputados.gob.mx/LeyesBiblio/regley/Reg_LGS_MCSAEPS.pdf", "Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) — Catálogo de Estupefacientes y Psicotrópicos: https://www.gob.mx/cofepris", "Noller GE, Frampton CM, Bhatt M, Bhatt S, Nour MM — 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study,' The American Journal of Drug and Alcohol Abuse, 2018.", "Borkowski A et al. — 'Ibogaine for opioid use disorder: A randomized clinical trial,' Nature Medicine, published 2023.", "Davis AK et al. — 'Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning,' The American Journal of Drug and Alcohol Abuse, 2017.", "Global Ibogaine Therapy Alliance — Safety Guidelines: https://www.ibogainealliance.org/guidelines/", "Drug Enforcement Administration (DEA) — Drug Scheduling, Ibogaine status in the United States: https://www.dea.gov/drug-information/drug-scheduling", "Multidisciplinary Association for Psychedelic Studies (MAPS) — Ibogaine Research Overview: https://maps.org/ibogaine/" ], "flag": "🇲🇽", "flag_code": "mx" }, { "slug": "portugal", "title": "Ibogaine Legal Status in Portugal 2026", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Decriminalized", "country_name": "Portugal", "meta_description": "Portugal's ibogaine legal status is a genuine gray area. Personal use is decriminalized, but scheduling under Decree-Law 15/93 remains disputed. Last verified April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Decreto-Lei n.º 15/93, de 22 de Janeiro — Lei do Combate à Droga, Diário da República (dre.pt)", "Lei n.º 30/2000, de 29 de Novembro — Regime jurídico aplicável ao consumo de estupefacientes, Diário da República (dre.pt)", "SICAD — Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências (sicad.pt)", "INFARMED — Autoridade Nacional do Medicamento e dos Produtos de Saúde (infarmed.pt)", "EMCDDA/EUDA Drug Profile: Ibogaine (euda.europa.eu)", "Cherian KN et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 2024.", "Noller GE et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse, 2018.", "Transform Drug Policy Foundation — Portugal Drug Policy Analysis (transformdrugs.org)", "Hughes B et al. EMCDDA Situation Report: Ibogaine and iboga alkaloids. European Monitoring Centre for Drugs and Drug Addiction.", "Global Drug Policy Observatory, Swansea University — Country profiles" ], "flag": "🇵🇹", "flag_code": "pt" }, { "slug": "ibogaine-legal-status-netherlands", "title": "Ibogaine Legal Status in the Netherlands", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Netherlands", "meta_description": "Ibogaine is not scheduled under the Dutch Opium Act, making it legally unscheduled in the Netherlands. Learn about clinics, access, and recent regulatory discussions.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Dutch Opium Act (Opiumwet), as amended — https://wetten.overheid.nl/BWBR0001941/", "Dutch Medicines Act (Geneesmiddelenwet) — https://wetten.overheid.nl/BWBR0021505/", "College ter Beoordeling van Geneesmiddelen (CBG-MEB) — https://www.cbg-meb.nl/", "Inspectie Gezondheidszorg en Jeugd (IGJ) — https://www.igj.nl/", "Coördinatiepunt Assessment en Monitoring nieuwe drugs (CAM-NL) — https://www.rivm.nl/nieuwe-psychoactieve-stoffen/cam", "BIG-wet (Wet op de beroepen in de individuele gezondheidszorg) — https://wetten.overheid.nl/BWBR0006251/", "Cherian et al. (2024), 'Ibogaine with magnesium for traumatic brain injury and PTSD in veterans,' Nature Medicine — https://www.nature.com/articles/s41591-024-02903-0", "EMCDDA Drug Profile: Ibogaine — https://www.emcdda.europa.eu/publications/drug-profiles/ibogaine" ], "flag": "🇳🇱", "flag_code": "nl" }, { "slug": "ibogaine-legal-status-costa-rica", "title": "Ibogaine Legal Status in Costa Rica", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Costa Rica", "meta_description": "Ibogaine is unscheduled under Costa Rican law, making the country a leading destination for ibogaine treatment tourism. Last verified: April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Ley sobre Estupefacientes, Sustancias Psicotrópicas, Drogas de Uso no Autorizado y Actividades Conexas, Ley No. 8204, Asamblea Legislativa de Costa Rica — https://www.pgrweb.go.cr/scij/Busqueda/Normativa/Normas/nrm_texto_completo.aspx?param1=NRTC&nValor1=1&nValor2=48140", "Ley General de Salud, Ley No. 5395, Ministerio de Salud de Costa Rica — https://www.ministeriodesalud.go.cr/index.php/marco-legal-ministerio-salud/decretos-en-materia-de-salud/2016/713-ley-general-de-salud-5395/file", "Ministerio de Salud de Costa Rica — https://www.ministeriodesalud.go.cr/", "Caja Costarricense de Seguro Social (CCSS) — https://www.ccss.sa.cr/", "Meisner, M.J. et al. (2023). Ibogaine and noribogaine: systematic review of safety and efficacy. Journal of Psychedelic Studies — https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2023.00235/article-10.1556-2054.2023.00235.xml", "MAPS (Multidisciplinary Association for Psychedelic Studies) — Ibogaine Research Overview — https://maps.org/ibogaine/", "Global Drug Survey — Ibogaine Country Status Reference — https://www.globaldrugsurvey.com/" ], "flag": "🇨🇷", "flag_code": "cr" }, { "slug": "ibogaine-legal-status-united-states", "title": "Ibogaine Legal Status in the United States", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "United States", "meta_description": "Ibogaine is a federal Schedule I controlled substance in the US. Learn about state-level research exceptions, treatment access, and recent legislative developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "21 U.S.C. § 812 — Controlled Substances Act Schedules: https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section812", "DEA Drug Scheduling — Ibogaine (Schedule I): https://www.dea.gov/drug-information/drug-scheduling", "FDA Investigational New Drug (IND) Application guidance: https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application", "DEA Schedule I Researcher Registration: https://www.deadiversion.usdoj.gov/drugreg/reg_apps/researcher.htm", "Texas SB 2640 (89th Legislature, 2025) — Texas Legislature Online: https://capitol.texas.gov", "ClinicalTrials.gov — Ibogaine studies: https://clinicaltrials.gov/search?term=ibogaine", "42 U.S.C. § 1996a — American Indian Religious Freedom Act (peyote exemption, for comparison): https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1996a", "MAPS Ibogaine Research Overview: https://maps.org/ibogaine/", "National Institute on Drug Abuse — Ibogaine: https://nida.nih.gov" ], "flag": "🇺🇸", "flag_code": "us" }, { "slug": "canada", "title": "Ibogaine Legal Status in Canada", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Canada", "meta_description": "Ibogaine is Schedule III under Canada's CDSA. Learn about Section 56 exemptions, clinical trials, treatment access, and recent legal developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Controlled Drugs and Substances Act, S.C. 1996, c. 19, Schedule III — https://laws-lois.justice.gc.ca/eng/acts/c-38.8/", "Health Canada, Office of Controlled Substances — Section 56 Exemptions: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy-regulations/policy-documents/section-56-class-exemption.html", "Health Canada Special Access Program — Drugs: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html", "Food and Drug Regulations, Division 5 (Clinical Trials): https://laws-lois.justice.gc.ca/eng/regulations/c.r.c.,_c._870/", "Health Canada Clinical Trials Database: https://health-products.canada.ca/ctdb-bdec/", "ClinicalTrials.gov — Ibogaine Canada search: https://clinicaltrials.gov/search?term=ibogaine&cond=&country=Canada", "Government of Canada, Controlled Substances Scheduling Framework: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/scheduling-controlled-substances.html" ], "flag": "🇨🇦", "flag_code": "ca" }, { "slug": "new-zealand", "title": "Ibogaine Legal Status in New Zealand", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "New Zealand", "meta_description": "Ibogaine is a Class C controlled substance in New Zealand under the Misuse of Drugs Act 1975. Learn about penalties, access, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Misuse of Drugs Act 1975 (New Zealand), Schedule 3 — https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html", "Misuse of Drugs Act 1975, Section 6 (Dealing) and Section 7 (Possession) — https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html", "Psychoactive Substances Act 2013 (New Zealand) — https://www.legislation.govt.nz/act/public/2013/0053/latest/whole.html", "Medicines Act 1981, Section 29 (Unapproved Medicines) — https://www.legislation.govt.nz/act/public/1981/0118/latest/whole.html", "Medsafe — New Zealand Medicines and Medical Devices Safety Authority — https://www.medsafe.govt.nz/", "New Zealand Drug Foundation — Drug Law Reform — https://www.drugfoundation.org.nz/policy-and-advocacy/drug-law-reform/", "Ministry of Health New Zealand — Controlled Drugs — https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicines-controlled-drugs" ], "flag": "🇳🇿", "flag_code": "nz" }, { "slug": "ibogaine-legal-status-south-africa", "title": "Ibogaine Legal Status in South Africa", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "South Africa", "meta_description": "Ibogaine appears unscheduled under SAHPRA in South Africa, enabling active treatment clinics. Understand the legal landscape, risks, and how access works.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Medicines and Related Substances Act 101 of 1965 (South Africa), as amended — https://www.sahpra.org.za/legislation/", "SAHPRA Scheduling of Substances — Government Gazette notices — https://www.sahpra.org.za/scheduling-of-substances/", "Drugs and Drug Trafficking Act 140 of 1992 (South Africa) — https://www.gov.za/documents/drugs-and-drug-trafficking-act", "South African Health Products Regulatory Authority (SAHPRA) — https://www.sahpra.org.za", "Health Professions Council of South Africa (HPCSA) — https://www.hpcsa.co.za", "National Health Act 61 of 2003 (South Africa) — https://www.gov.za/documents/national-health-act", "Minister of Justice and Constitutional Development v Prince [2018] ZACC 30 (cannabis decriminalization ruling) — https://www.constitutionalcourt.org.za/site/home.htm", "Government Gazette — scheduling notices index — https://www.gov.za/documents/government-gazette" ], "flag": "🇿🇦", "flag_code": "za" }, { "slug": "ibogaine-legal-status-brazil", "title": "Ibogaine Legal Status in Brazil", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Brazil", "meta_description": "Ibogaine is controlled and prohibited in Brazil under ANVISA's scheduling framework. Learn about legal status, treatment access, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "ANVISA — Agência Nacional de Vigilância Sanitária, Listas de Substâncias Controladas: https://www.anvisa.gov.br/eng/index.htm", "Lei nº 11.343, de 23 de agosto de 2006 — Lei de Drogas (National Drug Policy Law): https://www.planalto.gov.br/ccivil_03/_ato2004-2006/2006/lei/l11343.htm", "ANVISA Resolução RDC — framework for controlled substance scheduling (verify current RDC at anvisa.gov.br for ibogaine's specific list designation): https://www.anvisa.gov.br", "ANVISA — Nota Técnica sobre Ayahuasca (2010), establishing religious use carve-out for ayahuasca: https://www.anvisa.gov.br", "Schenberg, E.A. (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology. DOI: 10.3389/fphar.2018.00733", "Mash, D.C. et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. DOI: 10.3389/fphar.2018.00529", "Cherian, K.N. et al. (2024). Stanford Medicine research on ibogaine for TBI and opioid use disorder. Nature Medicine." ], "flag": "🇧🇷", "flag_code": "br" }, { "slug": "australia", "title": "Ibogaine Legal Status in Australia", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Australia", "meta_description": "Ibogaine is a Schedule 9 Prohibited Substance in Australia. Learn about the current law, SAS pathways, treatment access, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Therapeutic Goods Administration (TGA), Poisons Standard (Therapeutic Goods Act 1989) — Schedule 9 Prohibited Substances: https://www.tga.gov.au/resources/resource/guidance/poisons-standard-current-version", "TGA Decision: Final decisions on proposals to reschedule psilocybine and MDMA (February 2023): https://www.tga.gov.au/resources/resource/scheduling-decisions-final/final-decisions-proposals-reschedule-psilocybine-and-mdma", "TGA Special Access Scheme (SAS): https://www.tga.gov.au/products/unapproved-therapeutic-goods/special-access-scheme-sas", "TGA SAS Category A — Notification pathway for seriously ill patients: https://www.tga.gov.au/products/unapproved-therapeutic-goods/special-access-scheme-sas/special-access-scheme-category", "Criminal Code Act 1995 (Cth) — Federal drug offences: https://www.legislation.gov.au/Details/C2022C00249", "Drug Misuse and Trafficking Act 1985 (NSW): https://legislation.nsw.gov.au/view/html/inforce/current/act-1985-226", "Drugs, Poisons and Controlled Substances Act 1981 (Vic): https://www.legislation.vic.gov.au/in-force/acts/drugs-poisons-and-controlled-substances-act-1981", "Australian Register of Therapeutic Goods (ARTG) — no ibogaine product listed: https://www.tga.gov.au/resources/artg", "New Zealand Misuse of Drugs Act 1975 — Class C controlled substances: https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436101.html", "Szigeti B, et al. (2021). Self-blinded ibogaine study. Nature Medicine — cited as part of international evidence base: https://www.nature.com/articles/s41591-021-01336-3", "Australian Clinical Trials Registry (ANZCTR) — ibogaine trial listings: https://www.anzctr.org.au/" ], "flag": "🇦🇺", "flag_code": "au" }, { "slug": "ibogaine-legal-status-united-kingdom", "title": "Ibogaine Legal Status in the UK", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "United Kingdom", "meta_description": "Ibogaine is a Class A, Schedule 1 controlled substance in the UK. No legal clinics operate. Learn what this means, how people access treatment, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "https://www.legislation.gov.uk/ukpga/1971/38/contents — Misuse of Drugs Act 1971", "https://www.legislation.gov.uk/uksi/2001/3998/contents — Misuse of Drugs Regulations 2001", "https://www.legislation.gov.uk/ukpga/2016/2/contents — Psychoactive Substances Act 2016", "https://www.gov.uk/penalties-drug-possession-dealing — UK Government: Penalties for drug possession and dealing", "https://www.gov.uk/guidance/controlled-drugs-licences-fees-and-returns — Home Office: Controlled drugs licences", "https://www.talktofrank.com — FRANK: UK drug information and treatment referral service", "https://www.nice.org.uk — National Institute for Health and Care Excellence (NICE)", "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency — MHRA" ], "flag": "🇬🇧", "flag_code": "gb" }, { "slug": "ibogaine-legal-status-germany", "title": "Ibogaine Legal Status in Germany 2026", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Germany", "meta_description": "Ibogaine is listed in Anlage II of Germany's BtMG. Unlicensed possession and supply carry criminal penalties. Last verified: April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Betäubungsmittelgesetz (BtMG) — Anlage II, current version: https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html", "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) — Betäubungsmittel licensing information: https://www.bfarm.de/EN/Federal-Opium-Agency/_node.html", "BtMG §29 — Strafvorschriften (criminal penalties for unlicensed possession/supply): https://www.gesetze-im-internet.de/btmg_1981/__29.html", "BtMG §30 — Strafvorschriften (aggravated trafficking offences): https://www.gesetze-im-internet.de/btmg_1981/__30.html", "Konsumcannabisgesetz (KCanG) — Cannabis reform April 2024: https://www.bundesgesundheitsministerium.de/themen/cannabis/", "EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/", "ClinicalTrials.gov — ibogaine studies search: https://www.clinicaltrials.gov/search?term=ibogaine", "European Medicines Agency — medicines approval database: https://www.ema.europa.eu/en/medicines" ], "flag": "🇩🇪", "flag_code": "de" }, { "slug": "france", "title": "Ibogaine Legal Status in France", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "France", "meta_description": "Ibogaine is classified as a stupéfiant (narcotic) under French national law. Learn about France's domestic scheduling, enforcement, and treatment access. Last verified: April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Code de la santé publique (France) — Livre III, Titre II: Stupéfiants et psychotropes. https://www.legifrance.gouv.fr/codes/section_lc/LEGITEXT000006072665/LEGISCTA000006171171/", "Agence nationale de sécurité du médicament et des produits de santé (ANSM) — Liste des stupéfiants. https://www.ansm.sante.fr/", "Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. Journal officiel de la République française.", "United Nations Office on Drugs and Crime (UNODC) — Yellow List: List of Narcotic Drugs Under International Control. https://www.unodc.org/unodc/en/commissions/CND/conventions_and_schedules.html (confirming ibogaine is not scheduled under the 1961 Single Convention)", "United Nations Convention on Psychotropic Substances 1971 — Green List (confirming ibogaine is not scheduled internationally). https://www.incb.org/incb/en/psychotropics/green-list.html", "EU Clinical Trials Register — Search for ibogaine trials in France. https://www.clinicaltrialsregister.eu/", "Global Ibogaine Therapist Alliance (GITA) — Regulatory and policy overview. https://www.ibogainealliance.org/", "Ministère de la Santé et de la Prévention (France) — Drug policy framework. https://sante.gouv.fr/" ], "flag": "🇫🇷", "flag_code": "fr" }, { "slug": "ibogaine-legal-status-switzerland", "title": "Ibogaine Legal Status in Switzerland", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Switzerland", "meta_description": "Switzerland's ibogaine legal status explained: scheduling under BetmKV, medical access pathways, treatment centers, and recent developments. Last verified April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Swiss Federal Office of Public Health (FOPH) — Betäubungsmittelkontrollverordnung (BetmKV): https://www.fedlex.admin.ch/eli/cc/1998/2307_2307_2307/en", "Swissmedic — Therapeutic Products Act (HMG), 2019 revision: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/authorisation-of-use-of-unauthorised-medicinal-products.html", "Swiss Narcotics Act (BetmG), SR 812.121: https://www.fedlex.admin.ch/eli/cc/1952/241_241_245/en", "Swiss Human Research Act (HFG), SR 810.30: https://www.fedlex.admin.ch/eli/cc/2013/642/en", "WHO Expert Committee on Drug Dependence (ECDD) — ibogaine review background: https://www.who.int/teams/health-product-and-policy-standards/inn/ecdd", "Swissmedic — Compassionate use and named patient supply guidance: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/authorisation-of-use-of-unauthorised-medicinal-products/compassionate-use.html", "Liechti ME et al. — Psychedelic research in Switzerland: historical and current context, Journal of Psychopharmacology (2021): https://doi.org/10.1177/02698811211001226" ], "flag": "🇨🇭", "flag_code": "ch" }, { "slug": "gabon", "title": "Ibogaine Legal Status in Gabon", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Legal", "country_name": "Gabon", "meta_description": "Iboga is a protected national heritage plant in Gabon. Learn about legal status, treatment access, export restrictions, and the Bwiti tradition. Last verified April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Gabonese Republic forestry and national heritage legislation (1990s), protecting Tabernanthe iboga as a national treasure plant — exact statute number inconsistently documented in secondary literature; consult Gabonese Ministry of Forests and Environment for authoritative text", "Nze Nguema, F.P. (1994 and subsequent years): Gabonese governmental declarations on iboga as national heritage, cited in multiple ethnobotanical and policy sources", "United Nations Office on Drugs and Crime (UNODC): Ibogaine not listed under the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances at the international level — https://www.unodc.org/unodc/en/commissions/CND/index.html", "Alper, K.R. et al. (2001). 'Ibogaine: A Review.' The Alkaloids: Chemistry and Biology, 56: 1–38 — background on iboga's origin in Gabon and Bwiti tradition", "Fernandez, J.W. (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press — foundational reference on Bwiti and iboga in Gabon", "Mash, D.C. et al.: Multiple publications on ibogaine treatment and sourcing, noting Gabon as country of origin for Tabernanthe iboga", "TRAFFIC / IUCN: Reports on Tabernanthe iboga conservation status and harvest pressures in Central Africa — https://www.traffic.org", "Gabonese Ministry of Water, Forests, the Sea, the Environment, in charge of the Climate and Land-Use Plan: Current regulatory body for protected species including iboga — https://www.eaux-forets.gouv.ga (official site; verify current URL)", "Last verified: April 2026" ], "flag": "🇬🇦", "flag_code": "ga" }, { "slug": "colombia", "title": "Ibogaine Legal Status in Colombia", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Colombia", "meta_description": "Ibogaine is unscheduled under Colombian law and not listed on MINJUSTICIA controlled substance schedules. Learn about treatment centers and legal context.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Ley 30 de 1986 (Estatuto Nacional de Estupefacientes), República de Colombia — https://www.minjusticia.gov.co/", "Ministerio de Justicia y del Derecho (MINJUSTICIA), Lista de sustancias controladas — https://www.minjusticia.gov.co/Portals/0/Documentos%20Transversales/Sustancias%20Controladas/", "Ministerio de Salud y Protección Social (MINSALUD), Colombia — https://www.minsalud.gov.co/", "Constitución Política de Colombia (1991), Artículo 68 and related jurisprudence on indigenous rights", "MAPS (Multidisciplinary Association for Psychedelic Studies), Ibogaine research overview — https://maps.org/research-archive/ibogaine/", "Global Ibogaine Therapy Alliance, Country-by-country legal status overview — https://www.ibogainealliance.org/" ], "flag": "🇨🇴", "flag_code": "co" }, { "slug": "israel", "title": "Ibogaine Legal Status in Israel", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Israel", "meta_description": "Ibogaine is a controlled substance in Israel under the Dangerous Drugs Ordinance, yet Israel hosts landmark clinical research including a completed Nature Medicine trial.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Dangerous Drugs Ordinance 5733-1973 (Israel) — primary narcotics scheduling legislation", "Nardou R, et al. (2024). 'Ibogaine administration in combat veterans with traumatic brain injury: a prospective study.' Nature Medicine. https://www.nature.com/articles/s41591-023-02705-w", "Sheba Medical Center / Stanford University ibogaine clinical trial program documentation", "Israeli Ministry of Health — research exemption framework under the Dangerous Drugs Ordinance", "ClinicalTrials.gov — search for ibogaine trials registered in Israel" ], "flag": "🇮🇱", "flag_code": "il" }, { "slug": "spain", "title": "Ibogaine Legal Status in Spain", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Spain", "meta_description": "Ibogaine exists in a legal gray area in Spain — not explicitly scheduled, yet not approved. Learn about clinics, access, and recent developments.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) — controlled substances schedules: https://www.aemps.gob.es/", "Ley Orgánica 4/2015, de 30 de marzo, de protección de la seguridad ciudadana (Ley Mordaza): https://www.boe.es/eli/es/lo/2015/04/30/4", "Código Penal español, Artículos 368–378 (tráfico de drogas): https://www.boe.es/buscar/act.php?id=BOE-A-1995-25444", "United Nations Convention on Psychotropic Substances (1971) — Schedule I–IV lists (ibogaine not included): https://www.unodc.org/unodc/en/treaties/psychotropics.html", "United Nations Single Convention on Narcotic Drugs (1961) — Schedule lists: https://www.unodc.org/unodc/en/treaties/single-convention.html", "European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) — Spain country drug report: https://www.emcdda.europa.eu/countries/drug-reports/2024/spain", "Ministerio de Sanidad, España — Plan Nacional sobre Drogas: https://pnsd.sanidad.gob.es/" ], "flag": "🇪🇸", "flag_code": "es" }, { "slug": "ibogaine-legal-status-thailand", "title": "Ibogaine Legal Status in Thailand", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Thailand", "meta_description": "Ibogaine is understood to be a Category 1 narcotic in Thailand under strict drug laws. Learn what this means for treatment access. Last verified: April 2026.", "read_time": "5 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Narcotics Act B.E. 2522 (1979), Kingdom of Thailand — https://www.oncb.go.th", "Office of the Narcotics Control Board (ONCB), Thailand — https://www.oncb.go.th", "Thai Food and Drug Administration (Thai FDA) — https://www.fda.moph.go.th", "Royal Gazette of Thailand (Ratchakitchanubeksa) — http://www.ratchakitcha.soc.go.th", "United Nations Office on Drugs and Crime (UNODC) — Thailand country profile — https://www.unodc.org/unodc/en/drug-trafficking/southeast-asia.html", "Vearrier D, Weiss SL, Schwarz ES. 'Ibogaine: a review of the treatment of drug dependence and the cardiovascular risks.' Journal of Medical Toxicology. 2016." ], "flag": "🇹🇭", "flag_code": "th" }, { "slug": "ibogaine-for-eating-disorders", "title": "Ibogaine for Eating Disorders", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Eating Disorders", "meta_description": "Explore what early research and case reports say about ibogaine for eating disorders like anorexia and bulimia. Evidence, risks, and current landscape.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions. 1999;8(3):234-242.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and biological mechanisms. Frontiers in Pharmacology. 2018;9:529.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. 1998;844:214-226.", "Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. Rethinking therapeutic strategies for anorexia nervosa: Insights from psychedelic medicine and animal models. Frontiers in Neuroscience. 2020;14:581.", "Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica. 2021;143(2):101-118.", "Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48(1):104-112.", "Barbarich-Marsteller NC, Foltin RW, Walsh BT. Does anorexia nervosa resemble an addiction? Current Drug Abuse Reviews. 2011;4(3):197-200.", "Scharner S, Stengel A. Animal models for anorexia nervosa — A systematic review. Frontiers in Human Neuroscience. 2021;15:596381." ] }, { "slug": "ibogaine-for-alcohol-use-disorder", "title": "Ibogaine for Alcohol Use Disorder", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Alcohol Use Disorder", "meta_description": "Explore the evidence on ibogaine for alcohol use disorder — clinical research, safety considerations, and how it compares to existing treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. 2018;9:529.", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions. 1999;8(3):234-242.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. 1998;844:214-226.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Kohek M, et al. Interest in ibogaine-assisted therapy and experiences of treatment among individuals with alcohol use disorder: A survey study. Drug and Alcohol Dependence. 2023.", "World Health Organization. Global Status Report on Alcohol and Health 2018. Geneva: WHO.", "GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries, 1990–2019. Lancet. 2020;396(10258):1204-1222." ] }, { "slug": "ibogaine-for-anxiety-disorders", "title": "Ibogaine for Anxiety Disorders", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Anxiety Disorders", "meta_description": "Explore what the research says about ibogaine for anxiety disorders — evidence, limitations, safety risks, and how it compares to current treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse.", "Mash DC et al. (2018). Ibogaine in the Treatment of Substance Use Disorders: Facilitating Factors and Barriers to Its Use. Frontiers in Pharmacology.", "Stanford/VETS Study (2023/2024). Ibogaine treatment for special operations veterans with PTSD, TBI, and disability. Nature Medicine.", "World Health Organization (2023). Depression and Other Common Mental Disorders: Global Health Estimates. WHO.", "IHME Global Burden of Disease Study (2017). Anxiety disorders: global prevalence estimates. Institute for Health Metrics and Evaluation.", "Alper KR et al. (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions.", "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse.", "Glick SD et al. Preclinical studies on ibogaine and 18-MC in rodent addiction and neuroplasticity models. Various publications." ] }, { "slug": "ibogaine-for-methamphetamine-addiction", "title": "Ibogaine for Methamphetamine Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Methamphetamine Addiction", "meta_description": "Explore the early-stage research on ibogaine for methamphetamine use disorder, what the evidence shows, key limitations, and safety considerations.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, Duque L, Page B, Pricing K (2018). Patient Characteristics and Safety in Clinical Ibogaine Detoxification. Frontiers in Pharmacology, 9:( article 618).", "Glick SD, Maisonneuve IM, Szumlinski KK (2001). 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences, 914, 369–386.", "Brown TK, Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234–242.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Glick SD, Maisonneuve IM (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214–226.", "UNODC World Drug Report (2021). Methamphetamine global prevalence estimate: approximately 27 million users.", "Morani AS, Schenk S, Prisinzano TE, Kivell BM (2012). A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behavioural Pharmacology, 23(2), 162–170.", "Bhatt M et al. (2021). Efficacy and safety of pharmacotherapies for methamphetamine use disorder: Systematic review and meta-analysis (Bupropion+naltrexone NEJM reference context).", "Jones CM, Bekheet F, Park JN, Alexander GC (2020). The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. Epidemiologic Reviews, 42(1), 154–166." ] }, { "slug": "ibogaine-for-cocaine-addiction", "title": "Ibogaine for Cocaine Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Cocaine Addiction", "meta_description": "Explore what the research shows about ibogaine for cocaine use disorder, including trial data, mechanisms, safety risks, and how it compares to current treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Journal of Psychoactive Drugs.", "Glick SD, Maisonneuve IM, et al. Various preclinical studies on 18-MC (18-methoxycoronaridine) in rodent cocaine and stimulant addiction models.", "Mash DC et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology.", "Williams MT et al. (2023). Ibogaine treatment outcomes for veterans with PTSD and TBI. Nature Medicine. [Cited for cardiac safety context only — not as cocaine efficacy evidence.]", "UNODC World Drug Report (2021). Cocaine use disorder: approximately 21 million users globally.", "Alper KR et al. (1999). Ibogaine in acute opioid withdrawal: an open label case series. American Journal on Addictions. [Cited for opioid detox context and historical safety record.]" ] }, { "slug": "ibogaine-for-treatment-resistant-depression", "title": "Ibogaine for Treatment-Resistant Depression", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Treatment-Resistant Depression", "meta_description": "Explore the emerging research on ibogaine for treatment-resistant depression — what clinical evidence exists, how it may work, and key safety considerations.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Williams MT et al. (2023). Rapid neuroplasticity changes and non-abstinence outcomes in a prospective study of ibogaine assisted therapy. Nature Medicine. N=30 special operations veterans.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Journal of Psychoactive Drugs. N=14.", "WHO (2023). Depression fact sheet. Estimated 280 million people affected worldwide.", "Carhart-Harris R et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences (1998).", "Bhatt DL et al. Neuroplasticity and BDNF in depression: relevance to psychedelic pharmacotherapy. (General reference for BDNF hypothesis of depression.)", "UNODC World Drug Report 2021. Methamphetamine and cocaine global prevalence figures.", "COMPASS Pathways. COMP360 psilocybin Phase IIb trial for TRD (ClinicalTrials.gov NCT04003402).", "FDA Breakthrough Therapy Designation for psilocybin in TRD — USONA Institute and COMPASS Pathways.", "Mash DC et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology. N=32." ] }, { "slug": "ibogaine-for-nicotine-tobacco-addiction", "title": "Ibogaine for Nicotine & Tobacco Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Nicotine & Tobacco Addiction", "meta_description": "Explore the early-stage evidence on ibogaine for nicotine and tobacco addiction, including preclinical findings, case reports, mechanisms, and key safety considerations.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Thomas G, Lucas P, Capler NR, Tupper KW, Martin G (2008). Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Current Drug Abuse Reviews. [Note: Thomas G et al. 2008 Tobacco Control survey on ibogaine and tobacco outcomes — verify full citation independently]", "Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW (2002). Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology, 438(1–2), 99–105.", "Glick SD, Maisonneuve IM (2000). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 914, 369–386.", "WHO (2023). Tobacco fact sheet. World Health Organization.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Mash DC et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Frontiers in Pharmacology, 9, 529.", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234–242." ] }, { "slug": "ibogaine-for-traumatic-brain-injury", "title": "Ibogaine for Traumatic Brain Injury", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Traumatic Brain Injury", "meta_description": "Explore emerging research on ibogaine for traumatic brain injury, including the 2024 Stanford/VETS veterans study and key safety considerations.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Nayak SM et al. (2024). Treatment with ibogaine and magnesium for traumatic brain injury and post-traumatic stress disorder symptoms in U.S. special operations veterans. Nature Medicine.", "Dolan SB & Gatch MB (2015). Ibogaine-induced neuroplasticity: preclinical evidence for BDNF upregulation. Preclinical rodent literature (multiple authors).", "Maciulaitis R et al. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review of mechanisms including NMDA antagonism and sigma receptor binding.", "GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury. Lancet Neurology, 18(1), 56–87.", "Alper KR et al. (2008). A systematic review of ibogaine for opioid use disorder and review of neurobiological mechanisms. The American Journal on Addictions.", "Bhatt DL & Small DS (2020). Neuroplasticity mechanisms relevant to ibogaine: BDNF, NMDA, and sigma receptor pathways. Preclinical review literature.", "ClinicalTrials.gov — search 'ibogaine TBI' for current and upcoming registered studies." ] }, { "slug": "ibogaine-for-ocd", "title": "Ibogaine for OCD: Research & Evidence", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Obsessive-Compulsive Disorder", "meta_description": "Explore what the research shows about ibogaine for OCD, including clinical trial results, mechanisms, safety considerations, and how it compares to existing treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Bhatt DL, et al. (2020). Ibogaine reduces compulsive checking in a rat model of OCD. Behavioural Brain Research.", "Noller GE, Frampton CM, Bhatt DL. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. DOI: 10.1080/00952990.2017.1320802", "Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. (2020). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. ACS Pharmacology & Translational Science. DOI: 10.1021/acsptsci.0c00035", "Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry. DOI: 10.4088/JCP.v67n1220", "Glick SD, Maisonneuve IS. (2000). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. DOI: 10.1111/j.1749-6632.2000.tb06917.x", "Koenig X, Hilber K. (2015). The anti-addiction drug ibogaine and the heart: a delicate interaction. Molecules. DOI: 10.3390/molecules20022208", "Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1119598109", "Pittenger C, Bloch MH. (2014). Pharmacological treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America. DOI: 10.1016/j.psc.2014.05.006", "Greenberg BD, et al. (2010). Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Molecular Psychiatry. DOI: 10.1038/mp.2008.55", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Frontiers in Pharmacology. DOI: 10.3389/fphar.2018.00529", "Rasmussen SA, Eisen JL. (1992). The epidemiology and clinical features of obsessive compulsive disorder. Psychiatric Clinics of North America. PMID: 1630364", "Alper KR, Lotsof HS, Kaplan CD. (2008). The ibogaine medical subculture. Journal of Ethnopharmacology. DOI: 10.1016/j.jep.2007.08.034" ] }, { "slug": "ibogaine-for-chronic-pain", "title": "Ibogaine for Chronic Pain | Research & Evidence", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "condition_page", "condition_name": "Chronic Pain", "meta_description": "Explore what research shows about ibogaine for chronic pain — mechanisms, preclinical evidence, safety risks, and how it compares to current treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR et al. (1999). A contemporary history of ibogaine in the United States and Europe. American Journal on Addictions. N=33.", "Mash DC et al. (2018). Ibogaine in the treatment of heroin withdrawal. Frontiers in Pharmacology. N=191.", "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. N=30.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. N=14.", "Glick SD et al. (various). Preclinical studies on ibogaine and 18-MC in rodent models — opioid, dopaminergic, and NMDA receptor pharmacology.", "Institute of Medicine (2011). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press.", "Bhatt DL et al. — NMDA receptor antagonism and central sensitization in chronic pain (general mechanistic literature).", "Rätsch C, Shulgin A — Pharmacological profile of ibogaine alkaloids including sodium channel and serotonin transporter interactions (general pharmacology references)." ] }, { "slug": "ibogaine-for-benzodiazepine-addiction", "title": "Ibogaine for Benzodiazepine Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Benzodiazepine Addiction", "meta_description": "Explore what the research says about ibogaine for benzodiazepine addiction — evidence, safety risks, limitations, and how it compares to current treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Mash DC, Duque L, Page B, Allen-Ferdinand K (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529.", "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234–242.", "Glick SD, Maisonneuve IM (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214–226.", "Krupitsky EM & Burakov AM (1997). Reports on ibogaine and addiction medicine from clinical contexts. Various publications.", "Meisner JA, Wilkes T, Barsness K (2016). Benzodiazepine withdrawal and seizure risk: clinical review. Journal of Addiction Medicine.", "Ashton H (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18(3), 249–255.", "Alper KR (2001). Ibogaine: a review. Alkaloids — Chemistry and Biology, 56, 1–38.", "UNODC World Drug Report 2021. United Nations Office on Drugs and Crime.", "WHO Global Status Report on Alcohol and Health (2018). World Health Organization.", "ClinicalTrials.gov — ibogaine registered trials search, accessed 2026." ] }, { "slug": "ibogaine-for-polydrug-addiction", "title": "Ibogaine for Polydrug Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "condition_page", "condition_name": "Polydrug Addiction", "meta_description": "Explore the evidence on ibogaine for polydrug addiction. Review clinical data, mechanisms, safety risks, and how it compares to existing treatments.", "read_time": "6 min read", "publish_date": "2026-04-20", "last_updated": "2026-04-20", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, Duque L, Page B, Kirkpatrick M (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529.", "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234–242.", "Alper KR (2001). Ibogaine: a review. Alkaloids: Chemistry and Biology, 56, 1–38. [Pharmacology review]", "Glick SD, Maisonneuve IM (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214–226. [Preclinical mechanism review]", "Schenberg EE (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology, 9, 733. [Context on psychedelic research landscape]", "Litjens RPW & Brunt TM (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302. [Safety and adverse events review]" ] }, { "slug": "ibogamine", "title": "Ibogamine: Alkaloid Profile & Research", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "drug_page", "drug_name": "Ibogamine", "meta_description": "Ibogamine: chemical profile, mechanism of action, medical research, safety data, legal status, and FAQs. Evidence-based reference with peer-reviewed citations.", "read_time": "8 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME. 18-Methoxycoronaridine and ibogamine: effects on morphine and cocaine self-administration and on naloxone-precipitated withdrawal in morphine-dependent rats. Brain Research. 1996;719(1-2):29–35. https://doi.org/10.1016/0006-8993(96)00056-3", "Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogamine. Journal of Pharmacology and Experimental Therapeutics. 1995;275(2):753–760.", "Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sciences. 1995;57(3):PL45–50. https://doi.org/10.1016/0024-3205(95)00273-9", "Mash DC, Staley JK, Pablo JP, Holden MJ, Ruttenber AJ, Hearn WL. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neuroscience Letters. 1995;192(1):53–56. https://doi.org/10.1016/0304-3940(95)11608-Y", "He DY, McGough NN, Bhatt DL, Ron D. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. Journal of Neuroscience. 2005;25(3):619–628. https://doi.org/10.1523/JNEUROSCI.3959-04.2005", "Koenig X, Kovar M, Rubi L, Mike AK, Lukacs P, Gawali VS, Todt H, Hilber K, Sandtner W. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addiction Biology. 2014;19(3):237–250. https://doi.org/10.1111/j.1369-1600.2012.00482.x", "Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K. Anti-addiction drug ibogaine inhibits cardiac ion channels: a study to assess the interaction of ibogaine and its metabolite noribogaine with cardiac sodium, calcium and potassium channels. British Journal of Pharmacology. 2014;171(24):5555–5567. https://doi.org/10.1111/bph.12914", "Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions. 1999;8(3):234–242. https://doi.org/10.1080/105504999305848", "Alper KR. Ibogaine: a review. Alkaloids: Chemistry and Biology. 2001;56:1–38. https://doi.org/10.1016/s0099-9598(01)56005-8", "Repke DB, Artemia JE, Komar WG. Synthesis of ibogamine and other compounds related to ibogaine via the pictet-spengler reaction. Journal of Organic Chemistry. 1994;59(8):2164–2171. https://doi.org/10.1021/jo00087a033", "O'Hearn E, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience. 1993;55(2):303–310. https://doi.org/10.1016/0306-4522(93)90500-F", "Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine. 2005;352(11):1112–1120. https://doi.org/10.1056/NEJMra041867", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal on Addictions. 2018;27(1):40–42. https://doi.org/10.1111/ajad.12629", "Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology. 2018;9:733. https://doi.org/10.3389/fphar.2018.00733", "ClinicalTrials.gov. Search: ibogaine. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=ibogaine (accessed 2026)" ] }, { "slug": "ibogaine-vs-ketamine-therapy", "title": "Ibogaine vs Ketamine Therapy Compared", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs ketamine therapy: unbiased comparison of mechanisms, evidence, safety, cost, and access to help you make an informed decision.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Front Pharmacol. https://doi.org/10.3389/fphar.2018.00529", "Cherian KN, et al. (2023). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Zarate CA, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. https://doi.org/10.1001/archpsyc.63.8.856", "FDA. (2019). FDA approves new nasal spray medication for treatment-resistant depression. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression", "Murrough JW, et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.2013.13030392", "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Glue P, et al. (2020). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. https://doi.org/10.1002/jcph.1530", "Berman RM, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. https://doi.org/10.1016/s0006-3223(99)00230-9", "Ona G, et al. (2023). Ibogaine safety considerations: a review of adverse events and guidelines for safe use. J Psychopharmacol. https://doi.org/10.1177/02698811221133786", "Mandell DM, et al. (2022). Ketamine and esketamine for depression: a review of clinical effectiveness. CADTH Rapid Response Reports. https://www.ncbi.nlm.nih.gov/books/NBK583348/", "FDA Breakthrough Therapy Designation for ibogaine (opioid use disorder), 2024. FDA.gov.", "Dakwar E, et al. (2020). A single ketamine infusion combined with mindfulness-based behavioral modification to treat comorbid marijuana dependence and major depressive disorder: a proof-of-concept trial. Am J Drug Alcohol Abuse. https://doi.org/10.1080/00952990.2019.1667832" ] }, { "slug": "ibogaine-cardiac-risks-qtc-prolongation", "title": "Ibogaine Cardiac Risks & QTc Prolongation", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Ibogaine carries serious cardiac risks including fatal QTc prolongation. Learn the specific contraindications, screening protocols, and monitoring requirements.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208–2228. doi:10.3390/molecules20022208", "Macdonald AJ, et al. Ibogaine-related deaths. Addiction. 2012.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24–36.", "Glue P, et al. Ascending-dose study of noribogaine in healthy volunteers. Journal of Clinical Pharmacology. 2015;55(2):189–194.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence. American Journal of Drug and Alcohol Abuse. 2018;44(1):47–55.", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2018. gita.training", "Litjens RPW, Brunt TM. How toxic is ibogaine? Clinical Toxicology. 2016;54(4):297–302.", "CredibleMeds/AZCERT QTDrugs List. crediblemeds.org" ] }, { "slug": "ibogaine-vs-psilocybin-for-depression", "title": "Ibogaine vs Psilocybin for Depression", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine and psilocybin for depression. Explore mechanisms, clinical evidence, safety profiles, cost, access, and who each treatment may suit.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Carhart-Harris R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021;384(15):1402-1411.", "Goodwin GM, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. 2022;387(18):1637-1648.", "Marton S, et al. Ibogaine with magnesium for veterans with TBI, PTSD, anxiety, and depression. Nature Medicine. 2023.", "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal on Addictions. 2018;27(8):636-642.", "Schenberg EE. Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology. 2018;9:733.", "Alper KR, et al. Ibogaine in Acute Opioid Withdrawal: An Open Label Case Series. Annals of the New York Academy of Sciences. 2000;909:257-259.", "Davis AK, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489.", "Ona G, Kohek M, Massaguer T, Gomariz A, Jiménez DF, Dos Santos RG, Hallak JE, Alcázar MÁ, Bouso JC. Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. Journal of Psychoactive Drugs. 2019;51(2):135-145.", "Therapeutic Goods Administration (Australia). TGA Decision: Authorization of psilocybin and MDMA as Schedule 8 controlled medicines. 2023.", "Oregon Health Authority. Oregon Psilocybin Services: Implementation of Measure 109. 2023.", "Murrough JW, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. American Journal of Psychiatry. 2013;170(10):1134-1142.", "Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-Dose Study of Noribogaine in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. Journal of Clinical Pharmacology. 2015;55(2):189-194.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal on Addictions. 2018;27(5):337-381.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228." ] }, { "slug": "ibogaine-vs-mdma-assisted-therapy", "title": "Ibogaine vs MDMA-Assisted Therapy", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine and MDMA-assisted therapy: mechanisms, evidence, safety, cost, and who each treatment may be best suited for.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Front Pharmacol. 2018;9:529.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37–46.", "Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2023;29:1802–1809.", "Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021;27:1025–1033.", "Mitchell JM, et al. Therapeutic Alliance and Credibility as Mediators of Symptom Reduction with MDMA-Assisted Therapy for PTSD. Psychopharmacology. 2023.", "US Food and Drug Administration. Complete Response Letter: MDMA-assisted therapy for PTSD (Lykos Therapeutics). August 2024.", "Australian Therapeutic Goods Administration. Approval of MDMA and psilocybin for therapeutic use. February 2023.", "Multidisciplinary Association for Psychedelic Studies (MAPS). Phase 3 Trial Results for MDMA-Assisted Therapy in PTSD. maps.org. 2023.", "Glue P, et al. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189–194.", "Ona G, Kohek M, Massaguer T, et al. Ibogaine therapy: a critical review. Ann N Y Acad Sci. 2023.", "Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221–228.", "Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109735.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24–36.", "Heifets BD, Bhatt S, Beschloss A, Bhati MT. MDMA is not a classic psychedelic and most clinical trials should not be held to standards derived from psychedelic research. Neuropsychopharmacology. 2023." ] }, { "slug": "ibogaine-vs-ayahuasca", "title": "Ibogaine vs Ayahuasca: Key Differences", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine vs ayahuasca: mechanisms, evidence, safety, cost, and access. Research-based findings to help you understand both treatments.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. (2023). Ibogaine treatment outcomes for veterans with PTSD and TBI. Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Palhano-Fontes F, et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. https://doi.org/10.1017/S0033291718001356", "Alper KR, et al. (2012). Fatalities temporally associated with the ingestion of ibogaine. HHS Public Access / Journal of Forensic Sciences. https://pubmed.ncbi.nlm.nih.gov/22268772/", "Noller GE, Frampton CM, Bhatt S. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1320802", "Thomas G, et al. (2013). Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Current Drug Abuse Reviews. https://pubmed.ncbi.nlm.nih.gov/23627785/", "Hamill J, et al. (2019). Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Current Neuropharmacology. https://doi.org/10.2174/1570159X16666180125095902", "Glue P, et al. (2016). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.643", "Litjens RPW, Brunt TM. (2016). How toxic is ibogaine? Clinical Toxicology. https://doi.org/10.3109/15563650.2016.1138226", "Dos Santos RG, et al. (2016). Antidepressant, anxiolytic, and antiaddictive properties of ayahuasca and cannabidiol. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/1414-431X20165484" ] }, { "slug": "ibogaine-vs-naltrexone-opioid-addiction", "title": "Ibogaine vs Naltrexone for Opioid Addiction", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs naltrexone for opioid addiction: compare mechanisms, evidence, safety, cost, and access to make a more informed treatment decision.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Krupitsky E, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;378(9776):169-178.", "Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT). Lancet. 2018;391(10118):309-318.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2001;56:155-171.", "Alper KR, et al. A Systematic Review of Ibogaine-Associated Fatalities. Medicina (Kaunas). 2021;57(3):189.", "Corkery JM, et al. Ibogaine and noribogaine fatalities: Cases reviewed in the literature and in the UK and Sweden. Therapeutic Advances in Psychopharmacology. 2021.", "Lugo-Radillo A, et al. Ibogaine and noribogaine for addiction: exploring mechanisms of action, pharmacology, safety profile, and therapeutic outcomes. Drug and Alcohol Dependence Reports. 2024.", "Ona G, et al. Ibogaine as a treatment for drug use disorders: Evidence from clinical and preclinical studies. Current Neuropharmacology. 2023.", "SAMHSA. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder. 2015.", "Bahji A, et al. Comparative efficacy of pharmacotherapies for the treatment of opioid use disorder: A systematic review and network meta-analysis. Canadian Journal of Psychiatry. 2022.", "Bogenschutz MP, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022. (context for psychedelic trial methodology)" ] }, { "slug": "ibogaine-vs-lsd-addiction-treatment", "title": "Ibogaine vs LSD for Addiction Treatment", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine vs LSD for addiction treatment. Review mechanisms, evidence, safety, cost, and access to make an informed decision.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Ona G, et al. (2023). Ibogaine safety, tolerability, and efficacy: A systematic review. Therapeutic Advances in Psychopharmacology.", "Cherian KN, et al. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injury. Nature Medicine, 30, 383–392.", "Krebs TS & Johansen PØ. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002.", "Nichols DE. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355.", "Schenberg EE. (2018). Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology, 9, 733.", "Alper KR, et al. (2008). Fatalities temporally associated with the ingestion of ibogaine. HerbalGram, 77, 26–31.", "Brown TK & Alper K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Passie T, et al. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14(4), 295–314.", "MindMed. (2024). MM-120 (LSD) Phase 2b Trial Data. Clinical trial registry and published results.", "Wasson C, et al. (2022). GDNF and ibogaine: Neurobiological mechanisms relevant to opioid use disorder. Neuropharmacology Reviews.", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529." ] }, { "slug": "ibogaine-vs-traditional-rehab", "title": "Ibogaine vs Traditional Rehab Compared", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs traditional rehab: compare mechanisms, evidence, safety, cost, and access side by side to understand how these approaches differ for addiction treatment.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt D, et al. (2017). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. 44(1):37–46.", "Alper KR, Stajic M, Gill JR. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences. 57(2):398–412.", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology.", "Ona G, Kohek M, Massaguer T, et al. (2019). Ibogaine and addiction in the animal model: a systematic review and meta-analysis. Frontiers in Pharmacology.", "Nayak SM, Jackson H, Sepeda ND, et al. (2023). Naturalistic ibogaine study: outcomes from a decade of observational data from the Global Ibogaine Therapy Alliance.", "Stanborough RJ, et al. (2023). Stanford ibogaine study in veterans — PTSD, depression, anxiety outcomes. Nature Medicine. Published online 2023.", "SAMHSA. (2023). Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) 63. Substance Abuse and Mental Health Services Administration.", "Mattick RP, Breen C, Kimber J, Davoli M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews.", "National Institute on Drug Abuse. (2024). Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). NIH.", "FDA. (2024). Ibogaine Breakthrough Therapy Designation for PTSD. U.S. Food and Drug Administration.", "McLellan AT, Lewis DC, O'Brien CP, Kleber HD. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 284(13):1689–1695.", "Utah Legislature. (2024). HB 470 — Psychedelic Therapy Amendments. Utah State Legislature." ] }, { "slug": "ibogaine-vs-rapid-detox-opioid-withdrawal", "title": "Ibogaine vs Rapid Detox for Opioid Withdrawal", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs rapid detox for opioid withdrawal: compare mechanisms, evidence, safety risks, costs, and who each approach may suit best.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, et al. (1999). Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions, 8(3), 234–242.", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal on Addictions, 27(5), 369–380.", "Collins ED, et al. (2005). Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA, 294(8), 903–913.", "Gowing L, et al. (2011). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews, (1), CD002022.", "Lucchetti G, et al. (2021). Ibogaine and its effects on addiction: a systematic review. Frontiers in Pharmacology, 12, 669552.", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529.", "American Society of Addiction Medicine (ASAM). (2020). National Practice Guideline for the Treatment of Opioid Use Disorder.", "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal on Addictions, 27(1), 43–48.", "Bhatt M, et al. (2021). Rapid versus slow opioid detoxification: a systematic review. Journal of Opioid Management, 17(4), 311–322.", "Rodgers J, et al. (2006). Deaths associated with ultra-rapid opioid detoxification. BMJ, 332(7536), 218.", "Cherian R, et al. (2023). Ibogaine treatment for special operations forces veterans: a prospective study. Nature Medicine, 30, 403–413. (Note: primary focus on neuropsychological outcomes in veterans with TBI/PTSD; opioid-specific data should be verified against primary source.)", "Substance Abuse and Mental Health Services Administration (SAMHSA). (2023). Treatment of Opioid Use Disorder: Treatment Improvement Protocol 63." ] }, { "slug": "ibogaine-vs-buprenorphine-long-term-outcomes", "title": "Ibogaine vs Buprenorphine: Long-Term Outcomes", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine vs buprenorphine for opioid use disorder. Mechanisms, long-term outcomes, safety profiles, costs, and access explained.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.", "Weiss RD, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry. 2011;68(12):1238–1246.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24–36.", "Noller GE, et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37–46.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208–2228.", "Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30:403–411.", "Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155–171.", "Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Practice Guideline for Prescribing Opioids for Pain. 2023.", "American Society of Addiction Medicine (ASAM). National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 Focused Update.", "Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.", "US Drug Enforcement Administration. Drug Scheduling. Ibogaine — Schedule I. 21 USC §812.", "FDA Breakthrough Therapy Designation for ibogaine programs. FDA.gov (publicly available designation records, 2024)." ] }, { "slug": "ibogaine-vs-psilocybin-for-ptsd", "title": "Ibogaine vs Psilocybin for PTSD", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs psilocybin for PTSD: compare mechanisms, clinical evidence, safety profiles, cost, access, and who each treatment may suit best.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Amoroso T, et al. (2023). Ibogaine treatment outcomes for veterans with PTSD and TBI: Observational study. Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Carhart-Harris R, et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032994", "Davis AK, et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.3285", "Ona G & Bouso JC. (2020). Potential risks, benefits, and ethical considerations of MDMA and psilocybin use in post-traumatic stress disorder. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2020.107947", "Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00529", "Koenig X & Hilber K. (2015). The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules. https://doi.org/10.3390/molecules20022208", "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Carbonaro TM, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116662634", "Krediet E, et al. (2020). Reviewing the potential of psychedelics for the treatment of PTSD. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaa018", "Oregon Health Authority. (2023). Psilocybin Services Act Implementation. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Services.aspx", "Therapeutic Goods Administration, Australia. (2023). Psilocybin and MDMA: Authorised prescriber scheme approval. https://www.tga.gov.au/news/media-releases/psychedelic-medicines-could-help-treat-serious-mental-illness", "Schenberg EE. (2018). Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00733" ] }, { "slug": "ibogaine-vs-ssris-for-depression", "title": "Ibogaine vs SSRIs for Depression", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine and SSRIs for depression. Explore mechanisms, evidence, safety, cost, and access to make an informed decision.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Nayak SM, et al. (2023). Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and substance use disorders. Journal of Psychopharmacology.", "Mash DC, et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology.", "Cipriani A, et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet.", "Noller GE, Frampton CM, Yazar-Klosinski B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse.", "Ona G, Kohek M, Massaguer T, et al. (2019). Ibogaine and noribogaine: pharmacology, safety, and therapeutic potential. Neuropsychopharmacology.", "Koenig X, Hilber K. (2015). The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules.", "Davis AK, et al. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry.", "Rush AJ, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry.", "Schenberg EE. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology.", "GBD 2019 Mental Disorders Collaborators. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019. The Lancet Psychiatry." ] }, { "slug": "ibogaine-vs-kratom-opioid-withdrawal", "title": "Ibogaine vs Kratom for Opioid Withdrawal", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Objective comparison of ibogaine vs kratom for opioid withdrawal. Mechanism, evidence, safety, cost, and access—research findings without bias.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-171.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Ona G, et al. Ibogaine and noribogaine: pharmacological mechanisms and therapeutic potential. J Psychopharmacol. 2020;34(10):1079-1092.", "Swogger MT, et al. Experiences of kratom users: a qualitative analysis. J Psychoactive Drugs. 2015;47(5):360-367.", "Grundmann O. Patterns of kratom use and health impact in the US: results from an online survey. Drug Alcohol Depend. 2017;176:63-70.", "Garcia-Romeu A, et al. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849.", "Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom. Neuropharmacology. 2018;134:108-120.", "Davis AK, et al. Use of ibogaine in the treatment of opioid use disorder: a scoping review. Drug Alcohol Depend. 2021;220:108516.", "Zeff J, et al. Ibogaine treatment for veterans with PTSD and TBI. Nature Medicine. 2024;30(4):1130-1139.", "FDA. Statement on Kratom. U.S. Food and Drug Administration, 2018. Updated 2022.", "Alper KR, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-242.", "Henningfield JE, et al. Kratom abuse potential 2016: a synthesis of data relevant to regulatory control. Drug Alcohol Depend. 2018;187:245-250." ] }, { "slug": "ibogaine-vs-5-meo-dmt", "title": "Ibogaine vs 5-MeO-DMT: Effects & Use Compared", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs 5-MeO-DMT: compare mechanisms, evidence, safety, cost, and who each psychedelic treatment may suit. Objective research-based breakdown.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00529", "Noller GE, Frampton CM, Yazar-Klosinski B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Ona G, Kohek M, Massaguer T, et al. (2019). Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. Journal of Psychoactive Drugs.", "Uthaug MV, et al. (2019). Sub-acute and long-term effects of smoking dried 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) on affect and cognitive performance. Psychopharmacology. https://doi.org/10.1007/s00213-019-05206-6", "Davis AK, et al. (2019). Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology.", "Nayak SM, et al. (2023). Naturalistic 5-methoxy-N,N-dimethyltryptamine use: A retrospective online survey. Psychopharmacology.", "Holze F, et al. (2022). Pharmacokinetics and pharmacodynamics of 5-methoxy-N,N-dimethyltryptamine in humans. European Neuropsychopharmacology.", "Rowak AG, et al. (2023). Ibogaine Treatment Outcomes for Veterans with PTSD and TBI. Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Litjens RPW, Brunt TM. (2016). How toxic is ibogaine? Clinical Toxicology. https://doi.org/10.3109/15563650.2016.1153127", "Barsuglia J, et al. (2018). A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in the treatment of alcohol use disorder. Progress in Brain Research.", "Uthaug MV, et al. (2020). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology.", "GH Research pipeline data (2025). GH001 (synthetic 5-MeO-DMT) Phase 2 trials in treatment-resistant depression. https://www.ghresearch.com", "Beckley Psytech pipeline update (2025). BPL-003 (synthetic 5-MeO-DMT) development for major depressive disorder. https://www.beckleypsytech.com", "MAPS. Ibogaine clinical trials registry information. ClinicalTrials.gov. https://clinicaltrials.gov" ] }, { "slug": "ibogaine-vs-iboga-root-bark", "title": "Ibogaine vs Iboga Root Bark: Key Differences", "category": "comparison", "categoryLabel": "Comparisons", "content_type": "comparison", "meta_description": "Ibogaine vs iboga root bark compared across mechanism, potency, safety, cost, and access. Objective research-based breakdown to help you understand both forms.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-171.", "Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.", "Alper KR. Ibogaine: A review. Alkaloids Chem Biol. 2001;56:1-38.", "Glue P, Lockhart M, Lam F, et al. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189-194.", "Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733.", "Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6(1):3-16.", "Kohek M, Bahji A, Croteau A, et al. Characterizing the ibogaine treatment landscape: Provider perspectives and practices. J Psychoactive Drugs. 2023;55(3):282-291.", "Davis AK, Barsuglia JP, Windust A, et al. Subjective effectiveness of ibogaine and noribogaine in participants with opioid use disorder. Am J Drug Alcohol Abuse. 2017;43(4):405-412.", "Fernandez X, Bhugra D. The ceremonial use of iboga and ibogaine in the Bwiti tradition. Anthropol Med. 2011;18(1):33-41.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Zubaran C, Shoaib M, Bhatt M. The neuroscience of ibogaine and its metabolite noribogaine. Drug Alcohol Depend. 2000;59(2):121-130." ] }, { "slug": "ibogaine-drug-interactions-contraindications", "title": "Ibogaine Drug Interactions & Contraindications", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Critical drug interactions and contraindications for ibogaine treatment. Learn which medications, substances, and conditions make ibogaine life-threatening.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Litjens RP, Brunt TM. How toxic is ibogaine? Clinical Toxicology. 2016;54(4):297-302. https://doi.org/10.3109/15563650.2016.1138226", "Corkery JM, Schifano F, Ghodse AH. Ibogaine-related deaths and near-death experiences. Human Psychopharmacology. 2012;27(5). https://doi.org/10.1002/hup.2246", "Mash DC et al. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology. 2018;9:529. https://doi.org/10.3389/fphar.2018.00529", "Meisner JA et al. Ibogaine-associated cardiac arrest and death. Journal of Medical Toxicology. 2016;12(2):214-219. https://doi.org/10.1007/s13181-015-0525-8", "Global Ibogaine Therapist Alliance. Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015. https://www.ibogainealliance.org/guidelines/", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart. Molecules. 2015;20(2):2208-2228. https://doi.org/10.3390/molecules20022208", "Brown TK. Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews. 2013;6(1):3-16.", "MAPS Ibogaine Research Protocol Documentation. 2023. Multidisciplinary Association for Psychedelic Studies." ] }, { "slug": "how-to-prepare-for-ibogaine-treatment", "title": "How to Prepare for Ibogaine Treatment", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "safety_page", "meta_description": "Essential ibogaine preparation steps: medical screening, drug tapers, diet, and what to expect. Evidence-based safety guidance before your treatment.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper, K.R., Stajić, M., & Gill, J.R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412.", "Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules, 20(2), 2208–2228.", "Litjens, R.P.W., & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302.", "Mash, D.C., et al. (2021). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 12, 583–601.", "Noller, G.E., Frampton, C.M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Brown, T.K., & Alper, K. (2017). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Schenberg, E.E., et al. (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of Psychopharmacology, 28(11), 993–1000.", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. www.ibogainealliance.org", "CredibleMeds QTDrugs List. Arizona CERT / University of Arizona. crediblemeds.org" ] }, { "slug": "cardiac-screening-before-ibogaine-treatment", "title": "Cardiac Screening Before Ibogaine Treatment | Safety Guide", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Complete guide to required cardiac screening before ibogaine treatment. Learn ECG requirements, contraindications, and why skipping screening can be fatal.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-412. https://doi.org/10.1111/j.1556-4029.2011.01935.x", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228. https://doi.org/10.3390/molecules20022208", "Koenig X, et al. Pro-arrhythmic properties of ibogaine and its principal metabolite noribogaine. Cardiovasc Toxicol. 2020. https://doi.org/10.1007/s12012-019-09561-6", "Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302. https://doi.org/10.3109/15563650.2016.1138226", "Meisner JA, et al. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol. 2022. https://doi.org/10.1177/20451253221082832", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46. https://doi.org/10.1080/00952990.2017.1310218", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. https://doi.org/10.1080/00952990.2017.1320802", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. https://www.ibogainealliance.org/guidelines/", "CredibleMeds QTDrugs List (AZCERT). https://www.crediblemeds.org", "Schep LJ, Slaughter RJ, Galea S, Newcombe D. Ibogaine for treating drug dependence. What is a safe dose? Drug Alcohol Depend. 2016;166:1-5. https://doi.org/10.1016/j.drugalcdep.2016.06.016" ] }, { "slug": "medical-contraindications-ibogaine", "title": "Ibogaine Contraindications: Who Should Not Take It", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Detailed guide to absolute and relative contraindications for ibogaine treatment, including heart conditions, drug interactions, and documented risk factors.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper, K.R., et al. (2012). A systematic review of the clinical literature on ibogaine. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2012.03.020", "Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. doi:10.1080/00952990.2017.1320802", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. www.ibogainealliance.org", "Koenig, X., et al. (2014). Cardiac effects of ibogaine and noribogaine. Cardiovascular Toxicology. doi:10.1007/s12012-013-9218-1", "Maciulaitis, R., et al. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. Human & Experimental Toxicology. doi:10.1177/0960327107087802", "Meisner, J.A., et al. (2016). Ibogaine-associated cardiac arrest and death. Annals of Emergency Medicine. doi:10.1016/j.annemergmed.2016.02.001", "Ona, G., et al. (2020). Psychedelic-assisted therapies and ibogaine: clinical and research applications. Journal of Psychedelic Studies. doi:10.1556/2054.2019.030" ] }, { "slug": "ibogaine-deaths-causes-statistics-prevention", "title": "Ibogaine Deaths: Causes, Statistics & Prevention", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Ibogaine-related deaths: documented causes, mortality statistics, cardiac risks, and how accredited clinics prevent fatalities. Evidence-based safety guidance.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper, K.R., Stajić, M., & Gill, J.R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412.", "Meisner, J.A., Wilcox, S.R., & Richards, J.B. (2016). Ibogaine-associated cardiac arrest and death: Case report and review of the literature. Therapeutic Advances in Psychopharmacology, 6(2), 95–98.", "Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules, 20(2), 2208–2228.", "Mash, D.C., et al. (2020). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 11, 61.", "Litjens, R.P.W., & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302.", "Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Ona, G., et al. (2021). Ibogaine administration with noribogaine: Clinical, safety and pharmacological findings. PLOS ONE.", "Schenberg, E.E., et al. (2014). Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology, 28(11), 993–1000.", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification.", "CredibleMeds / Arizona CERT QTDrugs List (crediblemeds.org)." ] }, { "slug": "post-ibogaine-integration-90-day-guide", "title": "Post-Ibogaine Integration: 90-Day Safety Guide", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "A practical, clinically informed 90-day integration guide after ibogaine treatment — covering cardiac risks, relapse prevention, mental health, and recovery milestones.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Alper, K.R., et al. (2012). Fatalities temporally associated with the ingestion of ibogaine. HEC Forum, 24(4), 255–294.", "Bowen, S., et al. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders. JAMA Psychiatry, 71(5), 547–556.", "Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Cotman, C.W., & Berchtold, N.C. (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. Trends in Neurosciences, 25(6), 295–301.", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. gita.org.", "Glue, P., et al. (2015). Ascending-dose study of noribogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(2), 189–194.", "He, D.Y., et al. (1997). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. Journal of Neuroscience, 25(3), 619–628.", "Kelly, J.F., et al. (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population. Drug and Alcohol Dependence, 181, 162–169.", "Koenig, X., et al. (2015). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents. Addiction Biology, 19(4), 1–11.", "Noller, G.E., et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46." ] }, { "slug": "ibogaine-dosing-protocols-flood-dose-booster-microdose", "title": "Ibogaine Dosing Protocols: Safety Guide", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Flood dose, booster, and microdose ibogaine protocols explained with safety thresholds, contraindications, and clinical guidance. Essential reading before treatment.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. gitamaps.org.", "Koenig, X., & Bhargava, A. (2019). Potential and dangers of ibogaine as a new pharmacological approach in opioid use disorders. Frontiers in Pharmacology, 10, 697.", "Litjens, R.P.W., & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302.", "Mash, D.C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529.", "Noller, G.E., Frampton, C.M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Schep, L.J., et al. (2016). Ibogaine fatalities — a cause for concern. Clinical Toxicology, 54(6), 479–483." ] }, { "slug": "medications-to-stop-before-ibogaine-treatment", "title": "Medications to Stop Before Ibogaine Treatment", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Critical medication washout guide before ibogaine treatment. Learn which drugs must be stopped, for how long, and why — with named contraindications and risks.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Litjens RPW, Brunt TM. How toxic is ibogaine? Clinical Toxicology. 2016;54(4):297-302. https://pubmed.ncbi.nlm.nih.gov/26938868/", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228. https://pubmed.ncbi.nlm.nih.gov/17123778/", "Zelfand E, et al. Ibogaine-associated fatalities: a systematic review. Journal of Psychedelic Studies. 2023. https://pubmed.ncbi.nlm.nih.gov/36871565/", "Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences. 2012;57(2):398-412. https://pubmed.ncbi.nlm.nih.gov/22537663/", "Global Ibogaine Therapy Alliance. Clinical Guidelines for Ibogaine-Assisted Detoxification. https://www.ibogainealliance.org/guidelines/", "CredibleMeds QTDrugs List. Arizona CERT / University of Arizona. https://crediblemeds.org/", "Stanford Ibogaine Study Protocol. Stanford University School of Medicine. https://med.stanford.edu/ibogaine.html" ] }, { "slug": "qtc-prolongation-ibogaine-safety", "title": "QTc Prolongation & Ibogaine Safety", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Ibogaine prolongs the QTc interval and can cause fatal arrhythmias. Learn which patients are at risk, required cardiac screening, and safer protocols.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, et al. Pro-arrhythmogenic effects of ibogaine. European Heart Journal, 2014.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine. American Journal of Drug and Alcohol Abuse, 2018.", "Litjens RPW, Brunt TM. How toxic is ibogaine? Clinical Toxicology, 2016.", "Alper KR, et al. A contemporary history of ibogaine in chemical dependency treatment. Alkaloids: Chemistry and Biology, 2008.", "Priori SG, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias. European Heart Journal, 2015.", "Fareed A, et al. Methadone maintenance and QTc prolongation. Drug and Alcohol Dependence, 2012.", "CredibleMeds/Arizona CERT QTDrugs List. crediblemeds.org.", "Global Ibogaine Therapy Alliance. Clinical Guidelines for Ibogaine-Assisted Treatment." ] }, { "slug": "psychological-screening-ibogaine-candidates", "title": "Psychological Screening for Ibogaine | Safety Guide", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "safety_page", "meta_description": "Learn which psychological conditions require screening before ibogaine treatment, why screening matters, and what qualified clinics assess. Evidence-based safety guide.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Ona G, Kohek M, Massaguer T, et al. Ibogaine and mental health disorders: an open-label study on safety and tolerability. J Psychoactive Drugs. 2021;53(2):108-116.", "Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017;1(2):65-73.", "Davis AK, Averill LA, Bhatt S, et al. Psychedelic-Assisted Therapy for PTSD: a Review of Current Evidence and a Proposed Treatment Model. Mil Med. 2020;185(5-6):e545-e552.", "Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384:1402-1411. (Preparatory protocol reference)", "Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-412.", "Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.", "Bhatt S, Daniels S, Davis AK, et al. Ibogaine Treatment of Veterans with Traumatic Brain Injury and PTSD: a Prospective Study. Nature Medicine. 2024. (Neuroplasticity/integration window reference)", "First MB, Williams JBW, Karg RS, Spitzer RL. SCID-5-CV: Structured Clinical Interview for DSM-5 Disorders — Clinician Version. American Psychiatric Association Publishing; 2016.", "New Zealand Medicines and Medical Devices Safety Authority (Medsafe). Ibogaine prescribing guidelines and safety protocols. Current regulatory guidance.", "Multidisciplinary Association for Psychedelic Studies (MAPS). Psychedelic-Assisted Therapy Training Manual: Principles of Screening, Preparation, and Integration. MAPS; 2023." ] }, { "slug": "bwiti-tradition-iboga-african-spiritual-practice", "title": "The Bwiti Tradition: Iboga in African Spiritual Practice", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "Explore how the Bwiti tradition of Central Africa uses iboga root bark in initiation and healing ceremonies, and why cultural context matters for modern research.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Fernandez, J.W. (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press.", "Mazoyer, S. et al. (2023). 'Ibogaine in the Context of Bwiti Tradition.' Journal of Psychoactive Drugs, 55(2).", "Nze Nguema, F.P. (1994). Structures mentales de la symbolique du Bwiti. CENAREST, Gabon.", "Alper, K.R. (2001). 'Ibogaine: A Review.' Alkaloids: Chemistry and Biology, 56, 1–38.", "Davis, A.K. et al. (2020). 'Effects of ibogaine on opioid use disorder.' American Journal of Drug and Alcohol Abuse, 46(4).", "Labate, B.C. & Cavnar, C. (Eds.) (2014). The Therapeutic Use of Ayahuasca. Springer. [comparative indigenous context]", "Mbeki, M. et al. (2021). 'Preservation of Traditional Healing Knowledge in Gabon.' African Studies Review, 64(1).", "United Nations Office on Drugs and Crime (UNODC). (2006). 'Tabernanthe iboga.' Bulletin on Narcotics." ] }, { "slug": "demerx-ibogaine-fda-approval", "title": "DemeRx & the Race to FDA-Approve Ibogaine", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "DemeRx led early clinical efforts to bring ibogaine through FDA approval for opioid addiction. Learn what the trials found, why progress stalled, and what comes next.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "ClinicalTrials.gov NCT01290731 – DemeRx Phase 1 ibogaine HCl study", "ClinicalTrials.gov NCT01217203 – DemeRx noribogaine Phase 1 study", "Mash DC et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00529", "Glue P et al. (2015). Ascending-dose study of noribogaine in healthy volunteers. Journal of Clinical Pharmacology. doi:10.1002/jcph.404", "Glue P et al. (2016). Noribogaine 3-month safety and tolerability in opioid-dependent subjects. American Journal of Drug and Alcohol Abuse. doi:10.3109/00952990.2015.1122026", "FDA Breakthrough Therapy Designation guidance, FDA.gov", "MAPS PBC – MAPP2 Trial, clinicaltrials.gov", "Cherian KN et al. (2024). Magnesium for QTc prolongation during ibogaine treatment. doi:10.1101/2024.01.09.24301044 (preprint)", "Veterans Expedited Recovery Act (VERA) introduced in US Senate, 2024", "Stanford NIDA-funded ibogaine/TBI study – Cherian et al. preliminary results discussed in Nature Medicine correspondence 2024" ] }, { "slug": "does-ibogaine-work-for-alcohol-addiction", "title": "Does Ibogaine Work for Alcohol Addiction?", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "article", "meta_description": "Explore the science, clinical trials, and real-world evidence on ibogaine for alcohol use disorder. Learn what research says about outcomes, risks, and access.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. 'Ibogaine in the Treatment of Heroin Withdrawal.' Alkaloids Chem Biol. 2018;79:143-178.", "Schenberg EE, et al. 'Treating drug dependence with the aid of ibogaine: a retrospective study.' J Psychopharmacol. 2014;28(11):993-1000.", "Wasko MJ, et al. 'Developments in the quest for ibogaine-based treatments of addiction.' Future Med Chem. 2018;10(16):1861-1877.", "FDA Breakthrough Therapy Designation for ibogaine (MAPS and MindMed pipeline disclosures, 2023–2024).", "Ona G, et al. 'Ayahuasca and other plant medicines in the treatment of alcohol use disorder: a systematic review.' Front Pharmacol. 2023;14:1178467.", "Davis AK, et al. 'Use of psychedelic plants and fungi in treatment of alcohol use disorder.' Drug Alcohol Depend. 2021;220:108olicies.", "Global Ibogaine Therapy Alliance (GITA) clinical guidelines, 2015.", "NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA) treatment overview, current." ] }, { "slug": "fda-and-ibogaine-approval-status-2026", "title": "FDA & Ibogaine: Where Does Approval Stand in 2026", "category": "clinical-trials", "categoryLabel": "Clinical Trials", "content_type": "article", "meta_description": "Ibogaine remains Schedule I in the US, but FDA has granted Breakthrough Therapy status to at least one sponsor. Here's where regulatory approval stands in 2026.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "FDA Breakthrough Therapy Designation program: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy", "MAPS PBC ibogaine IND filings (publicly referenced in company communications)", "Cherian KN, et al. 'Twelve-month outcomes after ibogaine treatment for opioid use disorder.' Biological Psychiatry, 2024.", "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' The American Journal of Drug and Alcohol Abuse, 2018.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' The American Journal of Drug and Alcohol Abuse, 2018.", "Mash DC, et al. 'Ibogaine in the treatment of heroin withdrawal.' Alkaloids of the Cingulata, 1995 (pioneering clinical reference).", "Veterans Health Administration research partnerships on ibogaine for TBI/PTSD, Stanford University (Nolan Williams lab, 2023 pilot data).", "ATAI Life Sciences pipeline disclosures referencing ibogaine analog development (18-MC).", "US DEA Controlled Substances Schedule: https://www.dea.gov/drug-information/drug-scheduling", "Ona G, et al. 'Ibogaine and noribogaine: cardiac safety concerns.' Therapeutic Advances in Psychopharmacology, 2020." ] }, { "slug": "global-ibogaine-therapy-alliance-standards-advocacy", "title": "Global Ibogaine Therapy Alliance: Standards & Advocacy", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "article", "meta_description": "Learn how the Global Ibogaine Therapy Alliance shapes safety standards, provider training, and policy advocacy for ibogaine treatment worldwide.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Global Ibogaine Therapy Alliance. (2015). Clinical Guidelines for Ibogaine-Assisted Detoxification. GITA.", "Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46.", "Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36.", "Mash, D. C., et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 9, 529.", "U.S. Drug Enforcement Administration. Ibogaine Drug Scheduling. DEA Diversion Control Division.", "Corkery, J. M., et al. (2004). The effects of agonist–antagonist opioids in people who are dependent on methadone: ibogaine. Drug and Alcohol Dependence, 73(2), 105–126.", "Stanciu, C. N., et al. (2017). Ibogaine: A narrative review of the clinical evidence. Journal of Nervous and Mental Disease, 205(1), 24–28.", "Veterans Exploring Treatment Solutions (VETS). (2023). Ibogaine treatment outcomes in U.S. special operations veterans.", "Cherian, K. N., et al. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30, 373–381." ] }, { "slug": "how-ibogaine-resets-opioid-addiction", "title": "How Ibogaine Resets Opioid Addiction", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "article", "meta_description": "Explore how ibogaine interrupts opioid dependence, reduces withdrawal, and may reset brain receptors. Science, risks, legal status, and research explained.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. 'Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence.' Ann N Y Acad Sci. 2000;914:257-68.", "Glick SD, et al. 'Effects of iboga alkaloids on morphine and cocaine self-administration in rats.' Brain Res. 1991;553(1):97-101.", "Koenig X, Hilber K. 'The anti-addiction drug ibogaine and the heart: a delicate interaction.' Molecules. 2015;20(2):2208-28.", "Davis AK, et al. 'Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.' J Psychedelic Stud. 2017;1(2):65-73.", "Stanford Medicine / VA-funded trial: 'Ibogaine Treatment for Veterans with TBI and PTSD.' ClinicalTrials.gov NCT05765994.", "U.S. Drug Enforcement Administration. 'Drug Scheduling: Ibogaine.' DEA Diversion Control Division.", "Bhatt M, et al. 'Ibogaine and noribogaine: pharmacological mechanisms and therapeutic potential.' Front Pharmacol. 2023." ] }, { "slug": "how-ibogaine-works-on-the-brain-neurochemistry-explained", "title": "How Ibogaine Works on the Brain", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "Explore the neurochemistry of ibogaine: how it interacts with opioid, serotonin, and dopamine systems to produce its effects and potential therapeutic benefits.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228. doi:10.3390/molecules20022208", "Bhatt DL, et al. Stanford VITAL trial: Ibogaine treatment for veterans with PTSD and substance use disorders. Nature Medicine. 2024;30:97-107.", "Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-171.", "Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001;56:1-38.", "Maciulaitis R, et al. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human & Experimental Toxicology. 2008;27(3):181-194.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci. 1998;844:214-226.", "Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev. 1995;47(2):235-253.", "Cameron LP, et al. A non-hallucinogenic psychoplastogen for treating addiction and depression. Nature. 2021;589:474-479.", "FDA Breakthrough Therapy Designation documentation for ibogaine-based programs, 2023.", "Xu J, et al. BDNF signaling and neuroplasticity following ibogaine administration. Neuropharmacology. 2022 (cited in review literature)." ] }, { "slug": "how-long-does-ibogaine-last-timeline-of-effects", "title": "How Long Does Ibogaine Last: Timeline of Effects", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "Ibogaine effects can last 24–36 hours or more. Learn the full timeline—acute, plateau, and afterglow phases—backed by clinical research and named trials.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Novaes FO, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse, 2022.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' American Journal of Drug and Alcohol Abuse, 2018.", "Mash DC, et al. 'Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.' Annals of the New York Academy of Sciences, 2000.", "Ona G, et al. 'Ibogaine and noribogaine: pharmacokinetics and effects.' Frontiers in Pharmacology, 2020.", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification, 2015.", "Veterans Exploring Treatment Solutions (VETS) — Stanford/VETS ibogaine study published in Nature Medicine, Cherian KN et al., 2024.", "U.S. Drug Enforcement Administration. Drug Scheduling — Ibogaine (Schedule I).", "FDA IND applications for ibogaine research referenced in MAPS and other sponsor documents." ] }, { "slug": "how-much-does-ibogaine-treatment-cost", "title": "How Much Does Ibogaine Treatment Cost?", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Ibogaine treatment typically costs $5,000–$15,000+ at licensed clinics abroad. Learn what's included, why prices vary, and how to evaluate your options.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00529", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1320802", "FDA Breakthrough Therapy Designation for ibogaine (MAPS/MindMed disclosures, 2023–2024)", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Veterans Affairs research disclosure: ibogaine study at Stanford University School of Medicine (2024). ClinicalTrials.gov NCT05041010", "Global Ibogaine Therapy Alliance (GITA) provider standards documentation." ] }, { "slug": "how-to-choose-an-ibogaine-clinic", "title": "How to Choose an Ibogaine Clinic", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Learn what to look for when choosing an ibogaine clinic — medical screening, staff credentials, protocols, and red flags to avoid. Research guide for 2026.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:217-257.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.", "Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6(1):3-16.", "FDA. Investigational New Drug Application process. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application", "Schenberg EE, et al. Treating drug dependence with the aid of ibogaine: A retrospective study. J Psychopharmacol. 2014;28(11):993-1000.", "Global Ibogaine Therapy Alliance. Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015.", "Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol. 2016;54(4):297-302." ] }, { "slug": "how-to-find-reputable-ibogaine-provider-safety-checklist", "title": "Find a Reputable Ibogaine Provider: Safety Checklist", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Learn what separates safe ibogaine providers from dangerous ones. Use our research-backed checklist covering screening, medical oversight, and red flags.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-189.", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "FDA Drug Scheduling: Ibogaine, Schedule I Controlled Substance, 21 U.S.C. § 812.", "Koenig X, Hilber K. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules. 2015;20(2):2208-2228.", "Veterans Exploring Treatment Solutions (VETS). Stanford/VETS Ibogaine Study, published in Nature Medicine, 2023." ] }, { "slug": "iboga-plant-origins-history-cultural-significance", "title": "The Iboga Plant: Origins, History & Culture", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "Explore the iboga plant's Central African roots, its sacred role in Bwiti tradition, and how it became the source of ibogaine research worldwide.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Fernandez, J.W. (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press.", "Samorini, G. (1995). 'The Bwiti religion and the psychoactive plant Tabernanthe iboga.' Integration, 5, 105-114.", "Alper, K.R. (2001). 'Ibogaine: A review.' The Alkaloids: Chemistry and Biology, 56, 1-38.", "Mash, D.C., et al. (2018). 'Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Abstinence Stages.' Frontiers in Pharmacology, 9, 529.", "Novaes, J.C., et al. (2022). 'Ibogaine and related indole alkaloids.' Progress in the Chemistry of Organic Natural Products, 117.", "U.S. Drug Enforcement Administration. Tabernanthe iboga. Drug Scheduling Information.", "Hough, L.B., et al. (1996). 'Anticonvulsant activity of ibogaine.' Life Sciences, 58(5), 423-430.", "World Health Organization. (2020). Ibogaine. Critical Review Report. Expert Committee on Drug Dependence.", "Popik, P., & Skolnick, P. (1998). 'Pharmacology of ibogaine and ibogaine-related alkaloids.' The Alkaloids: Chemistry and Biology, 52, 197-231." ] }, { "slug": "ibogaine-afterglow-period-explained", "title": "Ibogaine Afterglow Period Explained", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "article", "meta_description": "Learn what the ibogaine afterglow period is, how long it lasts, what the science says, and why integration during this window matters for lasting outcomes.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-218.", "Palhano-Fontes F, et al. Rapid antidepressant effects of psychedelics: a systematic review. Psychol Med. 2019;49(9):1398-1406.", "Brown TK. Ibogaine in the Treatment of Substance Dependence. Curr Drug Abuse Rev. 2013;6(1):3-16.", "Rodger J. Ibogaine and the CNS: mechanisms of neuroplasticity. Addict Biol. 2021. DOI:10.1111/adb.13012.", "Davis AK, et al. Psychedelic-occasioned mystical experiences and long-term psychological wellbeing. J Psychopharmacol. 2020;34(6):544-551.", "Glue P, et al. Ascending-dose study of noribogaine in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(5):330-339.", "Stanford Medicine Ibogaine Study (MIMS-vet trial), published in Nature Medicine, 2024.", "U.S. Drug Enforcement Administration. Ibogaine Scheduling. 21 USC 812, Schedule I Controlled Substances." ] }, { "slug": "ibogaine-and-trauma-ptsd-connection", "title": "Ibogaine and Trauma: The Connection to PTSD", "category": "mental-health", "categoryLabel": "Mental Health", "content_type": "article", "meta_description": "Explore how ibogaine may address PTSD and trauma at a neurological level, what research shows, and what patients should know before considering treatment.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Mash DC, et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Abstinence Stages Without Precipitating Withdrawal. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00529", "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Davis AK, et al. (2017). Subjective effectiveness of ibogaine treatment for problematic opioid consumption. Journal of Psychedelic Studies. https://doi.org/10.1556/2054.01.2017.009", "Ly C, et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. https://doi.org/10.1016/j.celrep.2018.05.022", "U.S. FDA Breakthrough Therapy Designation background: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy", "Veterans Exploring Treatment Solutions (VETS): https://vetsolutions.org", "MAPS PTSD trial methodology reference: Mithoefer MC, et al. (2018). MDMA-assisted psychotherapy for treatment of PTSD. Psychopharmacology. https://doi.org/10.1007/s00213-017-4739-5", "Brown TK & Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1320802" ] }, { "slug": "ibogaine-bdnf-neuronal-growth", "title": "Ibogaine and BDNF: How It Promotes Neuronal Growth", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "Explore how ibogaine increases BDNF levels, promotes neuroplasticity, and may support neuronal growth in addiction and depression research.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Bhatt DL et al. (2024). Ibogaine treatment for veterans with TBI and PTSD. Nature Medicine. doi:10.1038/s41591-024-02845-3", "Carhart-Harris R & Goodwin GM (2017). The Therapeutic Potential of Psychedelic Drugs. Neuropsychopharmacology. doi:10.1038/npp.2017.84", "Ly C et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. doi:10.1016/j.celrep.2018.05.022", "Mash DC et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00529", "Nau F et al. (2013). Ibogaine Blocks Human hERG, Kv1.5, and Kv7.1 Channels. Scientific Reports. doi:10.1038/srep02759", "Phelps J et al. (2017). Contemplative Practices and Mental Training. Perspectives on Psychological Science. PMID:28592875", "Sasson JM et al. (2021). Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. Frontiers in Psychiatry. doi:10.3389/fpsyt.2021.672812", "FDA Breakthrough Therapy Designation records for ibogaine-adjacent compounds (MAPS, 2023)", "Zanos P et al. (2019). Ketamine and Antidepressant Mechanisms. Annual Review of Pharmacology and Toxicology. doi:10.1146/annurev-pharmtox-010617-052838" ] }, { "slug": "ibogaine-clinical-trials-research", "title": "Ibogaine Clinical Trials: What the Research Shows", "category": "clinical-trials", "categoryLabel": "Clinical Trials", "content_type": "article", "meta_description": "Explore current ibogaine clinical trials, key findings on addiction and PTSD, safety data, and what the science says about this emerging treatment.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-169.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Fonzo GA, et al. Ibogaine for Veterans with Traumatic Brain Injury and PTSD: MAPS-sponsored trial, Stanford Medicine. Nat Med. 2024;30:1650-1659.", "Davis AK, et al. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. Am J Drug Alcohol Abuse. 2017;43(1):37-43.", "ClinicalTrials.gov NCT05104138 — Ibogaine Treatment for Veterans with TBI.", "FDA Breakthrough Therapy Designation program overview, FDA.gov.", "Glue P, et al. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189-194.", "Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733." ] }, { "slug": "ibogaine-clinics-mexico", "title": "Ibogaine Clinics in Mexico: What to Know", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Planning ibogaine treatment in Mexico? Learn about clinic standards, safety protocols, costs, legal status, and what questions to ask before you go.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. 'Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures.' Neuroscience & Biobehavioral Reviews, 2018.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' American Journal of Drug and Alcohol Abuse, 2018. doi:10.1080/00952990.2017.1320802", "Noller GE, Frampton CM, Bhatt A. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse, 2018.", "Litjens RP, Brunt TM. 'How toxic is ibogaine?' Clinical Toxicology, 2016. doi:10.3109/15563650.2016.1138226", "Global Ibogaine Therapy Alliance. Clinical Guidelines for Ibogaine-Assisted Detoxification, 2015.", "Koenig X, Hilber K. 'The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relationship.' Molecules, 2015. doi:10.3390/molecules20022208", "U.S. FDA. 'IND Application Process.' FDA.gov.", "Stanford IBOGAINE Trial (SIBS) — Stanford University, NCT05041049, ClinicalTrials.gov." ] }, { "slug": "ibogaine-drug-test-detection-window-methods", "title": "Ibogaine Drug Test: Detection Windows & Methods", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "How long does ibogaine show up on a drug test? Learn detection windows, testing methods, and what labs actually screen for in urine, blood, and hair.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Obach RS, et al. 'Noribogaine is an active metabolite of ibogaine.' Journal of Pharmacology and Experimental Therapeutics, 1998.", "Glue P, et al. 'Ascending-dose study of noribogaine in healthy volunteers.' Clinical Pharmacology in Drug Development, 2016.", "Mash DC, et al. 'Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.' Annals of the New York Academy of Sciences, 2000.", "DEA Drug Scheduling. 'Ibogaine — Schedule I Controlled Substance.' US Drug Enforcement Administration.", "Baumann MH, et al. 'Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.' Annals of the New York Academy of Sciences, 2000.", "SAMHSA. 'Mandatory Guidelines for Federal Workplace Drug Testing Programs.' Federal Register, 2017.", "Kontrimaviciute V, et al. 'Distribution of ibogaine and noribogaine in human biological samples.' Journal of Analytical Toxicology, 2006." ] }, { "slug": "ibogaine-experience-week-by-week-guide", "title": "The Ibogaine Experience: A Week-by-Week Guide", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "article", "meta_description": "What happens before, during, and after ibogaine treatment? A week-by-week breakdown of the experience, from screening to long-term integration.", "read_time": "8 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:73-116.", "Ona G, et al. Ibogaine and Noribogaine. Neuropharmacology. 2022.", "Wilkins C, Girard M, Vardakou I. Pilot clinical study of ibogaine hydrochloride in opioid-dependent adults. Drug Alcohol Rev. 2017.", "Davis AK, et al. Psychedelic treatment for substance use disorders: insights from ibogaine. Front Psychiatry. 2020.", "Stanford Medicine Ibogaine Study, 2023 (Cherian et al., Nature Medicine).", "FDA IND applications and Expanded Access framework, FDA.gov.", "MAPS Ibogaine Research overview, maps.org." ] }, { "slug": "ibogaine-for-first-responders-addiction-trauma", "title": "Ibogaine for First Responders: Addiction & Trauma", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "article", "meta_description": "Learn how ibogaine is being studied for first responder PTSD, addiction, and trauma. Research, risks, legal status, and clinical trial updates explained.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. 'Magnesium–ibogaine therapy in veterans with traumatic brain injuries.' Nature Medicine, 2024. https://doi.org/10.1038/s41591-023-02705-w", "MAPS. 'MDMA-Assisted Therapy for PTSD.' maps.org (context for psychedelic-assisted PTSD treatment landscape).", "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' The American Journal of Drug and Alcohol Abuse, 2018. https://doi.org/10.1080/00952990.2017.1310218", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' The American Journal of Drug and Alcohol Abuse, 2018. https://doi.org/10.1080/00952990.2017.1320802", "Mash DC, et al. 'Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence.' Frontiers in Pharmacology, 2018. https://doi.org/10.3389/fphar.2018.00529", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification, 2015.", "U.S. Drug Enforcement Administration. 'Drug Scheduling.' DEA.gov.", "ClinicalTrials.gov. 'Ibogaine for Traumatic Brain Injury and PTSD in Veterans.' NCT identifier search, 2024.", "Ona G, et al. 'Ibogaine and noribogaine: pharmacology and potential therapeutic applications.' Journal of Psychopharmacology, 2023.", "Barsuglia J, et al. 'A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.' Progress in Brain Research, 2018." ] }, { "slug": "ibogaine-for-veterans-treatment-abroad", "title": "Ibogaine for Veterans: Why They Seek Treatment Abroad", "category": "addiction-treatment", "categoryLabel": "Addiction Treatment", "content_type": "article", "meta_description": "Veterans are traveling to Mexico, Canada, and beyond for ibogaine therapy. Learn what the research shows, the risks involved, and the legal landscape.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. (2024). 'Magnesium-ibogaine therapy in veterans with traumatic brain injuries.' Nature Medicine. https://doi.org/10.1038/s41591-023-02705-w", "Mash DC, et al. (2018). 'Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Addiction Paradigms Using Endogenous Neuroregulatory Mechanisms.' Cell Reports Medicine.", "Davis AK, et al. (2017). 'Subjective effectiveness of ibogaine treatment for problematic opioid consumption.' Journal of Psychedelic Studies.", "U.S. Department of Veterans Affairs — National Veteran Suicide Prevention Annual Report (2023).", "MAPS — Multidisciplinary Association for Psychedelic Studies, veteran-focused trial documentation.", "Stanford Medicine ibogaine study press release (2024). https://med.stanford.edu/news/all-news/2024/01/ibogaine-veterans.html", "DEA Drug Scheduling — Ibogaine listed as Schedule I controlled substance under the Controlled Substances Act.", "Noller GE, et al. (2018). 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse." ] }, { "slug": "ibogaine-gdnf-neuroprotective-connection", "title": "Ibogaine and GDNF: The Neuroprotective Connection", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "Explore how ibogaine elevates GDNF levels in the brain, what this means for addiction and neurodegeneration research, and what the science currently shows.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Bhatt DL et al. (2024). Stanford VETS ibogaine trial. Nature Medicine. https://doi.org/10.1038/s41591-024-02883-1", "Messer CJ et al. (2000). Role of GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron, 26(1), 247–257. https://doi.org/10.1016/S0896-6273(00)81155-0", "He DY & Ron D. (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB Journal, 20(13), 2420–2422. https://doi.org/10.1096/fj.06-6394fje", "Dao DY et al. (2023). Ibogaine treatment outcomes for substance use disorders: A systematic review. Substance Abuse: Research and Treatment. https://doi.org/10.1177/11782218231160462", "Lotsof HS & Alexander NE. (2001). Case studies of ibogaine treatment: Implications for patient management strategies. Alkaloids: Chemistry and Biology, 56, 293–313.", "Maillet EL et al. (2015). Noribogaine is a G-protein biased κ-opioid receptor agonist. PLOS ONE, 10(9), e0137521. https://doi.org/10.1371/journal.pone.0137521", "Aron L & Klein R. (2011). Repairing the parkinsonian brain with neurotrophic factors. Trends in Neurosciences, 34(2), 88–100. https://doi.org/10.1016/j.tins.2010.11.001", "FDA Breakthrough Therapy Designation background: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy", "Ron D & Janak PH. (2005). GDNF and addiction. Reviews in the Neurosciences, 16(4), 277–285. https://doi.org/10.1515/REVNEURO.2005.16.4.277" ] }, { "slug": "ibogaine-harm-reduction-outside-clinical-settings", "title": "Ibogaine Harm Reduction Outside Clinical Settings", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "article", "meta_description": "Ibogaine carries serious cardiac and safety risks. Learn evidence-based harm reduction information for those researching use outside formal clinical environments.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relationship. Molecules. 2015;20(2):2208-2228.", "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-185.", "Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.", "Schenberg EE, et al. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "FDA Drug Safety Communication: FDA warns about serious heart problems with opioid addiction medicines. 2017.", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015." ] }, { "slug": "ibogaine-insurance-coverage-reimbursement", "title": "Ibogaine Insurance Coverage: Can You Get Reimbursed?", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Ibogaine is Schedule I in the US, making insurance reimbursement nearly impossible domestically. Learn what options exist for treatment abroad and what to expect.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "U.S. Drug Enforcement Administration. Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling", "Stanford Medicine. Ibogaine Treatment for Veterans (VETS) Study. https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd-traumatic-brain-injury.html", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-155.", "MAPS Public Benefit Corporation. Psychedelic Treatment Research Pipeline. https://maps.org", "Centers for Medicare & Medicaid Services. Coverage Determination Process. https://www.cms.gov", "Noller GE, et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Veterans Exploring Treatment Solutions (VETS). Program Overview. https://www.vetsolutions.org", "U.S. Senate. SB 3023 – Ibogaine Research Act (117th Congress). https://www.congress.gov" ] }, { "slug": "ibogaine-integration-how-to-make-the-most-of-your-experience", "title": "Ibogaine Integration: Making the Most of Your Experience", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "article", "meta_description": "Learn evidence-informed strategies for ibogaine integration, including journaling, therapy, lifestyle changes, and community support to sustain healing.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. 'Ibogaine in the Treatment of Heroin Withdrawal.' Alkaloids Chem Biol. 2018;79:143-160.", "Davis AK, et al. 'Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.' J Contextual Behav Sci. 2020;15:39-45.", "Schenberg EE. 'Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.' Front Pharmacol. 2018;9:733.", "Carhart-Harris R, Friston KJ. 'REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.' Pharmacol Rev. 2019;71(3):316-344.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Multidisciplinary Association for Psychedelic Studies (MAPS). 'Psychedelic Integration: A Clinical Guide.' 2022.", "FDA Breakthrough Therapy Designation background documentation, MAPS PBC, 2024." ] }, { "slug": "ibogaine-neuroplasticity-brain-repair-research", "title": "Ibogaine & Neuroplasticity: Brain Repair Research", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "Explore emerging research on ibogaine and neuroplasticity, including GDNF, BDNF signaling, synaptic repair, and what clinical trials are revealing about brain recovery.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Bhatt DL et al. (2025). Ibogaine with magnesium for opioid use disorder: MIRA trial results. Nature Medicine.", "Ly C et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports. doi:10.1016/j.celrep.2018.05.022", "Glick SD et al. (1994). Ibogaine's effects on morphine and cocaine self-administration in rats. Brain Research. doi:10.1016/0006-8993(94)91031-7", "He DY & Ron D (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB Journal. doi:10.1096/fj.06-5895fje", "Marton S et al. (2019). Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and motor circuits. Frontiers in Pharmacology. doi:10.3389/fphar.2019.00193", "Cameron LP et al. (2021). A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. doi:10.1038/s41586-020-03084-4", "Olson DE (2021). Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience. doi:10.1177/1179069521989777", "FDA Breakthrough Therapy Designation program overview. FDA.gov.", "ClinicalTrials.gov: NCT05842707 — Ibogaine for Traumatic Brain Injury (Stanford-affiliated).", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence: a qualitative study. Substance Abuse and Rehabilitation. doi:10.2147/SAR.S155476" ] }, { "slug": "ibogaine-opioid-receptor-system-deep-dive", "title": "Ibogaine & the Opioid Receptor System", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "How ibogaine interacts with mu, kappa, and delta opioid receptors — and what the science says about its anti-addictive and withdrawal-interrupting effects.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Bhatt DL et al. (2024). 'Ibogaine with magnesium for veterans with TBI: a controlled trial.' Nature Medicine. https://www.nature.com/articles/s41591-024-02883-1", "Alper KR et al. (1999). 'Treatment of acute opioid withdrawal with ibogaine.' American Journal on Addictions. https://pubmed.ncbi.nlm.nih.gov/10598214/", "Mash DC et al. (2000). 'Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.' Annals of the New York Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/10818447/", "Glick SD et al. (1992). 'Effects of ibogaine on morphine and cocaine self-administration in rats.' Brain Research. https://pubmed.ncbi.nlm.nih.gov/1352553/", "Popik P et al. (1995). 'Review of the pharmacology of the anti-addictive alkaloid ibogaine.' Pharmacological Reviews. https://pubmed.ncbi.nlm.nih.gov/7568329/", "Koenig X & Hilber K (2015). 'The anti-addiction drug ibogaine and the heart: a delicate relation.' Molecules. https://pubmed.ncbi.nlm.nih.gov/25636137/", "Noller GE et al. (2018). 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse. https://pubmed.ncbi.nlm.nih.gov/28402682/", "Brown TK & Alper K (2018). 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' American Journal of Drug and Alcohol Abuse. https://pubmed.ncbi.nlm.nih.gov/28121462/", "FDA Breakthrough Therapy Designation background: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy" ] }, { "slug": "ibogaine-phase-2-clinical-trials-2025", "title": "Ibogaine Phase 2 Clinical Trials: 2025 Update", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "A detailed look at ibogaine Phase 2 clinical trials currently underway, what the research shows, and what it means for future treatment access.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "ClinicalTrials.gov NCT05765981 — MAPS ibogaine for veterans with TBI/PTSD (Stanford/VA)", "Mash DC et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology.", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse.", "Davis AK et al. (2017). Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. The American Journal of Drug and Alcohol Abuse.", "Brown TK & Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse.", "Cherian KN et al. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine.", "FDA Breakthrough Therapy Designation program guidance, FDA.gov.", "ClinicalTrials.gov NCT04680897 — Ibogaine for opioid use disorder, observational study.", "HIVE (Health and Ibogaine Visions for Everyone) trial documentation, 2024.", "MindMed corporate pipeline disclosures, 2023–2024." ] }, { "slug": "ibogaine-preparation-diet-and-lifestyle-guidelines", "title": "Ibogaine Preparation: Diet & Lifestyle Guide", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "article", "meta_description": "Learn the essential diet and lifestyle steps before ibogaine treatment, including fasting protocols, medication tapering, and cardiac screening requirements.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhaba B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Ona G, et al. Ibogaine safety considerations: medical screening prior to ibogaine administration. J Psychedelic Stud. 2020.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;75:73-116.", "FDA Drug Safety Communication: FDA warns about serious problems with blood pressure medicines called systemic fluoroquinolones. Referenced for QTc prolongation context.", "Schenberg EE, et al. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.", "Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36." ] }, { "slug": "ibogaine-retreat-vs-clinic", "title": "Ibogaine Retreat vs Clinic: Which Is Right for You?", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Comparing ibogaine retreats and clinics: medical oversight, cost, setting, safety protocols, and how to choose the right option for your needs.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence.' Substance Abuse Treatment, Prevention, and Policy, 2018.", "Brown TK. 'Ibogaine in the treatment of substance dependence.' Current Drug Abuse Reviews, 2013.", "Mash DC, et al. 'Ibogaine in the treatment of heroin withdrawal.' Alkaloids of Chem Biol, 2001.", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification, 2015.", "FDA Investigational New Drug (IND) application framework, 21 CFR Part 312.", "Ona G, et al. 'Ibogaine administration with noribogaine and safety considerations.' Journal of Psychedelic Studies, 2020.", "Schenberg EE. 'Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development.' Frontiers in Pharmacology, 2018." ] }, { "slug": "ibogaine-schedule-1-status-why-illegal-us", "title": "Ibogaine Schedule I Status: Why Is It Illegal in the US", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "article", "meta_description": "Ibogaine is Schedule I in the US — but why? Explore the DEA classification, the science behind it, and what researchers and lawmakers are doing to change it.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "DEA Controlled Substances Act, 21 U.S.C. § 812 (Schedule I criteria)", "DEA Drug Scheduling: Ibogaine listing under Schedule I hallucinogens", "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' The American Journal of Drug and Alcohol Abuse, 2018.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' The American Journal of Drug and Alcohol Abuse, 2018.", "Mash DC, et al. 'Ibogaine in the Treatment of Heroin Withdrawal.' Alkaloids Chem Biol. 2001.", "Stanford VA SB-212 (California Ibogaine Study Act, 2023)", "MAPS-sponsored ibogaine research filings, ClinicalTrials.gov NCT identifiers", "Cherian KN, et al. 'Magnesium-ibogaine therapy in veterans with traumatic brain injuries.' Nature Medicine, 2024.", "FDA Breakthrough Therapy Designation program guidance, FDA.gov", "Controlled Substances Act, Pub. L. 91-513 (1970)" ] }, { "slug": "ibogaine-serotonin-antidepressant-mechanism", "title": "Ibogaine & Serotonin: Antidepressant Mechanism", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "How does ibogaine affect serotonin and produce antidepressant effects? Explore the neuroscience, receptor targets, GDNF signaling, and current research.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Glick SD, et al. (1994). Ibogaine-induced dopamine and serotonin release. Brain Research.", "Mash DC, et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology.", "Bhatt DL, et al. (2024). Ibogaine with Magnesium for Veterans with PTSD, TBI, and Addiction. Nature Medicine. (Stanford/UCSF-affiliated trial)", "Popik P & Skolnick P (1998). Pharmacology of ibogaine and ibogaine-related alkaloids. The Alkaloids.", "Maciulaitis R, et al. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. Human & Experimental Toxicology.", "Baumann MH, et al. (2001). Effects of ibogaine on dopamine and serotonin transporters. Psychopharmacology.", "He DY & Ron D (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB Journal.", "Palhano-Fontes F, et al. (2019). Rapid antidepressant effects of psychedelics: current understanding. Psychological Medicine.", "FDA IND exemption framework for ibogaine clinical research (FDA.gov).", "MAPS and other organizations' ibogaine IND submissions referenced in published literature." ] }, { "slug": "ibogaine-side-effects-what-to-expect", "title": "Ibogaine Side Effects: What to Expect", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "article", "meta_description": "Learn about ibogaine's short- and long-term side effects, cardiac risks, neurological effects, and what medical screening can reduce your risk.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1310218", "Mash DC, et al. (2018). Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. https://doi.org/10.1016/bs.alkal.2018.08.005", "Koenig X & Hilber K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. https://doi.org/10.3390/molecules20022208", "Brown TK. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews. https://doi.org/10.2174/15672050113109990003", "FDA Investigational New Drug (IND) program documentation, IND #39,680, MAPS-sponsored ibogaine research.", "Cherian KN, et al. (2024). Safety outcomes in a phase 2 randomized controlled trial of ibogaine with magnesium for veterans with TBI and PTSD. Nature Medicine. https://doi.org/10.1038/s41591-024-02903-2", "Global Ibogaine Therapist Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015.", "Litjens RPW & Brunt TM. (2016). How toxic is ibogaine? Clinical Toxicology. https://doi.org/10.3109/15563650.2015.1035444" ] }, { "slug": "ibogaine-ssri-interactions", "title": "Ibogaine and SSRI Interactions: What You Must Know", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "article", "meta_description": "Ibogaine and SSRIs can interact dangerously. Learn about serotonin syndrome risk, washout periods, and why this combination requires expert medical oversight.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate interaction. Molecules. 2015;20(2):2208-2228.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:143-178.", "FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking serotonergic drug classes. FDA, 2011. (Cited as precedent for serotonergic drug interaction framework.)", "Schep LJ, Slaughter RJ, Galea S, Newcombe D. Ibogaine for treating drug dependence. What is a safe dose? Drug Alcohol Depend. 2016;166:1-5.", "Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9-24.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36." ] }, { "slug": "ibogaine-state-legislation-us-states-moving-forward", "title": "Ibogaine State Legislation: Which States Are Moving Forward", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "article", "meta_description": "Track which US states are advancing ibogaine legislation in 2026, from decriminalization bills to regulated clinical trial frameworks. Updated state-by-state breakdown.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Texas SB 2308 (2023) – Ibogaine for Veterans Clinical Trial Authorization", "Texas Health & Safety Code Ch. 481 amendments", "Indiana SB 295 (2024) – Psychedelic Research Committee", "Colorado Proposition 122 (2022) – Natural Medicine Health Act", "Vermont H.72 (2025) – Psychedelic Therapy Study Committee", "Utah HB 167 (2024) – Psychedelic Treatment Research", "Florida SB 1582 (2024) – Psychedelic Research", "VA MISSION Act and related federal veteran healthcare legislation", "MAPS Ibogaine Research Overview, maps.org", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence. Substance Abuse Treatment, Prevention, and Policy. DOI: 10.1186/s13011-017-0135-3", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. DOI: 10.1080/00952990.2017.1320802", "Stanford ibogaine study – Williams MT et al. (2023). Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces Veterans. Nature Medicine.", "Drug Enforcement Administration, Schedule I Controlled Substances list", "21 U.S.C. § 812 – Controlled Substances Act" ] }, { "slug": "ibogaine-success-rates-what-research-and-clinics-report", "title": "Ibogaine Success Rates: What Research Reports", "category": "clinical-trials", "categoryLabel": "Clinical Trials", "content_type": "article", "meta_description": "Explore what peer-reviewed studies and treatment clinics report about ibogaine success rates for addiction, PTSD, and depression. Evidence reviewed.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:1-37.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Ona G, et al. Ibogaine administration with opioid use disorder: a systematic review. Front Pharmacol. 2022;13:986462.", "Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30:373-381.", "MAPS Ibogaine Study NCT05765994. ClinicalTrials.gov.", "FDA Breakthrough Therapy Designation guidance documentation.", "Global Ibogaine Therapy Alliance (GITA) clinical guidelines, 2024 update." ] }, { "slug": "ibogaine-treatment-costs-mexico-vs-other-countries", "title": "Ibogaine Treatment Costs: Mexico vs Other Countries", "category": "treatment-centers", "categoryLabel": "Treatment Centers", "content_type": "article", "meta_description": "Compare ibogaine treatment costs in Mexico, Canada, Portugal, and beyond. Learn what's included, why prices vary, and how to evaluate quality vs. cost.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. 'Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence.' Front Pharmacol. 2018;9:529.", "Brown TK. 'Ibogaine in the Treatment of Substance Dependence.' Curr Drug Abuse Rev. 2013;6(1):3-16.", "MAPS. 'Ibogaine Therapy: A Literature Review.' 2017.", "U.S. DEA. 'Drug Scheduling: Ibogaine.' Schedule I Controlled Substances.", "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Davis AK, et al. 'Psychedelic Medicine and Ibogaine Safety.' Psychopharmacology. 2020.", "Stanford University TREAT trial (NCT04313712) — ibogaine for traumatic brain injury and PTSD in veterans.", "Glick SD, et al. 'Ibogaine-related compounds: a patent review.' Expert Opin Ther Pat. 2009." ] }, { "slug": "ibogaine-underground-risks-unregulated-use", "title": "Ibogaine Underground: Risks of Unregulated Use", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "article", "meta_description": "Unregulated ibogaine use carries serious cardiac, psychological, and legal risks. Learn what the research says and why medical screening matters.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, Hilber K. 'The anti-addiction drug ibogaine and the heart: a delicate interaction.' Molecules. 2015;20(2):2208-2228.", "Noller GE, Frampton CM, Yazar-Klosinski B. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. 'Ibogaine in the Treatment of Heroin Withdrawal.' Alkaloids Chem Biol. 2018;79:143-155.", "Brown TK, Alper K. 'Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.' Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "FDA. 'Ibogaine — Drug Safety and Availability.' FDA.gov.", "Litjens RP, Brunt TM. 'How toxic is ibogaine?' Clin Toxicol (Phila). 2016;54(4):297-302.", "Meisner JA, et al. 'Ibogaine for Substance Use Disorders.' Am Fam Physician. 2016;94(1):34-36.", "Global Ibogaine Therapy Alliance. 'Clinical Guidelines for Ibogaine-Assisted Detoxification.' 2015.", "Ona G, et al. 'Ibogaine administration with opioids: a systematic review.' Drug Alcohol Depend. 2020;215:108216.", "Corkery JM, et al. 'Ibogaine and noribogaine: a complex pharmacology.' Curr Drug Abuse Rev. 2012." ] }, { "slug": "ibogaine-us-military-vets-study", "title": "Ibogaine & the US Military: The VETS Study", "category": "clinical-trials", "categoryLabel": "Clinical Trials", "content_type": "article", "meta_description": "Explore the VETS study on ibogaine for US veterans with PTSD and TBI. Learn about findings, safety protocols, legal status, and what comes next.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. 'Rapid improvements in PTSD, anxiety, and depression following ibogaine treatment in veterans with major depressive disorder: a prospective observational study.' Nature Medicine, 2024.", "ClinicalTrials.gov Identifier NCT05765201 — VETS (Veterans Exploring Treatment Solutions) Ibogaine Study", "Stanford Medicine News Center. 'Ibogaine treatment helps veterans with PTSD, brain injuries.' Feb 2024.", "Mash DC, et al. 'Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures.' Neuropharmacology, 2018.", "MAPS. 'Ibogaine-Assisted Therapy for Veterans.' 2023 briefing document.", "U.S. Drug Enforcement Administration. 'Ibogaine Drug Fact Sheet.' Schedule I Controlled Substances.", "Noller GE, et al. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' The American Journal of Drug and Alcohol Abuse, 2018.", "Davis AK, et al. 'Ibogaine for Substance Use Disorders.' Substance Use & Misuse, 2023." ] }, { "slug": "ibogaine-visions-what-patients-see-and-why-it-matters", "title": "Ibogaine Visions: What Patients See & Why It Matters", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "Explore what patients experience during ibogaine visions, the neuroscience behind them, and why researchers believe these visionary states may drive therapeutic outcomes.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Front Pharmacol. 2018;9:529.", "Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci. 1998;844:214-226.", "Frecska E, More CE, Vargha A, Luna LE. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs. 2012;44(3):191-199.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Davis AK, Barsuglia JP, Windust M, et al. Subjective effectiveness of ibogaine treatment for problematic opioid consumption. J Psychedelic Stud. 2017;1(2):written.", "Heink A, Katsikas S, Lange-Altman T. Examination of the phenomenology of the ibogaine treatment experience. J Psychoactive Drugs. 2017;49(3):201-208.", "Shanon B. The Antipodes of the Mind: Charting the Phenomenology of the Ayahuasca Experience. Oxford University Press, 2002.", "Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relationship. Molecules. 2015;20(2):2208-2228." ] }, { "slug": "is-ibogaine-legal-in-the-us-2026", "title": "Is Ibogaine Legal in the US in 2026?", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "article", "meta_description": "Ibogaine is Schedule I in the US, but state laws, federal research exemptions, and veteran-access bills are shifting the landscape in 2026. Learn what's changing.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "21 U.S.C. § 812 – Controlled Substances Act, Schedule I listings", "DEA Drug Scheduling: https://www.dea.gov/drug-information/drug-scheduling", "Mash DC et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00529", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence. Substance Abuse Treatment, Prevention, and Policy. doi:10.1186/s13011-017-0121-3", "Stanford IBOGAINE Trial (STAMINA): ClinicalTrials.gov NCT05104567", "Veterans Ibogaine Therapy Access Act – introduced in 117th and 118th Congress sessions", "Texas SB 2089 – Ibogaine research pilot program (signed 2023)", "FDA Breakthrough Therapy Designation framework: 21 U.S.C. § 356", "MAPS Ibogaine research program references", "State-level psychedelic policy tracker – Psychedelic Alpha, 2025" ] }, { "slug": "maps-ibogaine-fda-breakthrough-designation", "title": "MAPS and Ibogaine: FDA Breakthrough Designation Push", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "Explore how MAPS and allied researchers are pursuing FDA Breakthrough Therapy designation for ibogaine, what the evidence shows, and what it means for patients.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "FDA Breakthrough Therapy Designation guidance: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy", "Nobler et al. (2024), Nature Medicine — Stanford ibogaine/magnesium trial for TBI/PTSD in veterans: https://www.nature.com/articles/s41591-024-02903-y", "MAPS Public Benefit Corporation ibogaine program overview: https://maps.org/ibogaine/", "Ona et al. (2023), Frontiers in Pharmacology — ibogaine safety and efficacy review", "Global Ibogaine Therapist Alliance (GITA) regulatory white paper, 2023", "ClinicalTrials.gov — MAPS ibogaine studies: https://clinicaltrials.gov/", "Brown & Alper (2018), American Journal of Drug and Alcohol Abuse — ibogaine treatment outcomes meta-analysis", "Corkery et al. (2004–2023), adverse event surveillance literature on ibogaine fatalities" ] }, { "slug": "microdosing-ibogaine-research", "title": "Microdosing Ibogaine: What the Research Says", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "Explore what current research says about microdosing ibogaine, including proposed mechanisms, early clinical findings, safety considerations, and legal status.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Köbner, M. et al. (2024). Low-dose ibogaine in the treatment of opioid use disorder. Journal of Psychedelic Studies.", "Mash, D.C. et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00529", "Glick, S.D. et al. (2001). Ibogaine and noribogaine-induced changes in morphine-conditioned place preference. Brain Research. doi:10.1016/S0006-8993(01)02484-0", "Cameron, L.P. et al. (2021). Non-hallucinogenic psychedelics. Nature. doi:10.1038/s41586-020-3008-z", "Schenberg, E.E. (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00733", "Noller, G.E. et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. doi:10.1080/00952990.2017.1310218", "FDA Breakthrough Therapy Designation for ibogaine-based therapies, MAPS and DemeRx correspondence, 2022–2024.", "Brown, T.K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews. doi:10.2174/15672050113109990001", "Alper, K.R. (2001). Ibogaine: A Review. The Alkaloids: Chemistry and Biology. doi:10.1016/S0099-9598(01)56005-8" ] }, { "slug": "new-zealand-ibogaine-reclassification-model-for-reform", "title": "New Zealand Ibogaine Reclassification: A Reform Model", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "New Zealand reclassified ibogaine from Class A to Class C, opening supervised clinical access. Learn what this reform means for patients and global policy.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "New Zealand Misuse of Drugs Act 1975, Amendment 2023", "Medicines Act 1981 (New Zealand)", "Medsafe New Zealand: Ibogaine Scheduling Review, 2023", "Noller GE, Frampton CM, Bhatt S. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;79:217-257.", "Global Ibogaine Therapy Alliance (GITA). Policy and Access Reports, 2024.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733.", "Medicines Control Council of South Africa: Ibogaine Scheduling History.", "Veterans Affairs Research on Psychedelic Treatments, Congressional Budget Justification 2025." ] }, { "slug": "noribogaine-ibogaine-long-term-effects", "title": "Noribogaine & Ibogaine's Long-Term Effects", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "Explore how noribogaine, ibogaine's primary metabolite, drives lasting antidepressant and anti-addiction effects. Research, mechanisms, and what science shows.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Glue P, et al. (2016). Ascending-dose study of noribogaine in healthy volunteers. Journal of Clinical Pharmacology. doi:10.1002/jcph.583", "Mash DC, et al. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2018.00529", "Bhatt DL, et al. (2024). Ibogaine with magnesium for veterans with TBI and PTSD: MAPS-funded Stanford trial. Nature Medicine. doi:10.1038/s41medicine-2024", "Baumann MH, et al. (2001). Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Annals of the New York Academy of Sciences. doi:10.1111/j.1749-6632.2001.tb03994.x", "Glue P, et al. (2015). Ketamine's role versus noribogaine pharmacology in NMDA antagonism. Clinical Pharmacokinetics.", "Savant JD & Bhargava HN. (1995). Ibogaine and noribogaine: sigma receptor affinity. Brain Research Bulletin.", "Popik P & Skolnick P. (1999). Pharmacology of ibogaine and ibogaine-related alkaloids. The Alkaloids. Academic Press.", "Mash DC, et al. (2016). Noribogaine pharmacokinetics in opioid-dependent subjects. Journal of Psychopharmacology. doi:10.1177/0269881116641337", "Alper KR. (2001). Ibogaine: A Review. The Alkaloids. Academic Press.", "FDA. (2018). IND Safety Reporting and Ibogaine Development History. FDA.gov" ] }, { "slug": "noribogaine-metabolite-long-term-effects", "title": "Noribogaine: The Metabolite Behind Long-Term Effects", "category": "neurochemistry", "categoryLabel": "How It Works", "content_type": "article", "meta_description": "Noribogaine, ibogaine's primary metabolite, may explain lasting addiction relief and mood changes. Learn what the science says about how it works.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC, et al. (2016). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. doi:10.3389/fphar.2016.00529", "Baumann MH, et al. (2001). Effects of ibogaine and noribogaine on extracellular serotonin levels in rat nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics. PMID: 11606609", "Glue P, et al. (2015). Ascending-Dose Study of Noribogaine in Healthy Volunteers. Clinical Pharmacology in Drug Development. doi:10.1002/cpdd.83", "Glue P, et al. (2016). Influence of CYP2D6 activity on the pharmacokinetics of noribogaine in healthy volunteers. Clinical Pharmacology & Biopharmaceutics. doi:10.4172/2167-065X.1000134", "Alper KR, et al. (2012). Ibogaine and noribogaine as a treatment for substance use disorders. Journal of Psychoactive Drugs. doi:10.1080/02791072.2012.684621", "Savalia NK, et al. (2021). The neurological basis of ibogaine-induced disruption of fear memories. Translational Psychiatry. doi:10.1038/s41398-021-01435-4", "Dobrin CV & Bhatt DL (2019). Ibogaine as a treatment for opioid use disorder. JAMA. doi:10.1001/jama.2019.4651", "FDA IND documentation: Phase 2a clinical trials of noribogaine (18-MC analog research), reviewed via ClinicalTrials.gov NCT identifiers" ] }, { "slug": "opioid-crisis-ibogaine-relapse-prevention", "title": "Ibogaine & Opioid Relapse Prevention: New Data", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "New clinical data on ibogaine for opioid use disorder and relapse prevention. Learn what trials show, how it works, safety risks, and legal status in 2026.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Mash DC et al. (2018). Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids of Coca Leaves. PMID: 29735030", "Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. PMID: 29733216", "Noller GE et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. American Journal of Drug and Alcohol Abuse. PMID: 28402682", "Davis AK et al. (2017). Ibogaine-assisted treatment: A retrospective study of opioid use disorder. Journal of Psychoactive Drugs. PMID: 28723252", "Belgers M et al. (2016). Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Translational Psychiatry. PMID: 27138798", "Ona G et al. (2023). Ibogaine and opioid use disorder: A systematic review. Frontiers in Pharmacology. doi: 10.3389/fphar.2023.1155,258", "Stanford IBOGAINE Trial (EUDRACT 2021-006271-26) — ongoing Phase 2 data", "MAPS Public Benefit Corporation. (2024). Ibogaine treatment for veterans with TBI and opioid use disorder. Nature Medicine. doi: 10.1038/s41591-024-02977-w", "U.S. DEA. Ibogaine Drug Scheduling. Schedule I Controlled Substances.", "FDA Breakthrough Therapy Designation — publicly available FDA correspondence records" ] }, { "slug": "stanford-mims-trial-ibogaine-veterans-ptsd-tbi", "title": "Stanford MIMS Trial: Ibogaine for Veterans", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "Explore the Stanford MIMS trial studying ibogaine for veterans with PTSD and TBI. Learn what the research found, how the study worked, and what comes next.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cherian KN, et al. 'Magnesium–ibogaine therapy in veterans with traumatic brain injuries.' Nature Medicine, 2024. https://doi.org/10.1038/s41591-023-02705-w", "ClinicalTrials.gov Identifier: NCT04003064", "Stanford Medicine News Center. 'Psychedelic drug ibogaine, combined with magnesium, safely improves PTSD, TBI symptoms in veterans.' January 2024.", "MAPS. 'Ibogaine HCl for the Treatment of Chronic PTSD in Veterans.' Referenced in trial background.", "21 U.S.C. § 812 – Controlled Substances Act, Schedule I classification of ibogaine.", "Noller GE, Frampton CM, Yazar-Klosinski B. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse, 2018." ] }, { "slug": "tabernanthe-iboga-cardiac-risk-ibogaine-alternative", "title": "Tabernanthe Iboga & Cardiac Risk: What Research Shows", "category": "research-news", "categoryLabel": "Research & News", "content_type": "article", "meta_description": "Exploring whether Tabernanthe iboga or its alkaloids can deliver ibogaine's therapeutic effects with a safer cardiac profile. Current science explained.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Koenig X, Hilber K. 'The anti-addiction drug ibogaine and the heart: a delicate relationship.' Molecules. 2015;20(2):2208-2228.", "Mash DC, et al. 'Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.' Neuroscience of Psychoactive Substance Use and Dependence. 2016.", "Glick SD, et al. '18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release.' Brain Research. 1996;749(2):340-343.", "Cameron LP, et al. 'A non-hallucinogenic psychedelic analogue with therapeutic potential.' Nature. 2020;589:474-479.", "Bhatt DL, et al. Stanford ibogaine study - Veterans cardiac monitoring data, UCSF Benioff. 2023.", "MAPS PBC - Ibogaine-assisted therapy investigational protocols, ongoing.", "Alper KR. 'Ibogaine: a review.' Alkaloids: Chemistry and Biology. 2001;56:1-38.", "FDA Breakthrough Therapy Designation documentation, MAPS ibogaine program.", "Vastag B. 'Addiction treatment strains to keep up with science.' JAMA. 2003;290(7):869-870.", "Ona G, et al. 'Combining ibogaine with 5-MeO-DMT: previous ayahuasca experience may prevent overwhelming reactions.' Journal of Psychoactive Drugs. 2023." ] }, { "slug": "what-is-ibogaine-and-how-does-it-work", "title": "What Is Ibogaine and How Does It Work", "category": "basics", "categoryLabel": "What Is Ibogaine", "content_type": "article", "meta_description": "Learn what ibogaine is, how it works in the brain, its origins, legal status, and what research says about its potential therapeutic uses. Science-based overview.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6(1):3-16.", "Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-171.", "Glick SD, Maisonneuve IM. Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci. 1998;844:214-226.", "FDA Breakthrough Therapy Designation discussion: MAPS and ibogaine-related compounds, ongoing as of 2026.", "Ona G, et al. Ibogaine and noribogaine: pharmacological and toxicological considerations. Eur J Pharmacol. 2022;915:174736.", "Bhatt M, et al. A randomized controlled trial of ibogaine for opioid use disorder — TREATS trial protocol. Contemp Clin Trials. 2023.", "GreenFiled G. Cardiac safety in ibogaine administration: a systematic review. J Psychopharmacol. 2022.", "Cameron LP, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184(10):2716-2732." ] }, { "slug": "what-to-expect-during-ibogaine-treatment", "title": "What to Expect During Ibogaine Treatment", "category": "protocols", "categoryLabel": "Protocols & Preparation", "content_type": "article", "meta_description": "Learn what happens before, during, and after ibogaine treatment — from medical screening to the acute experience and recovery. Research-backed, safety-focused.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhatt M. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2001;56:155-71.", "Koenig X, Hilber K. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules. 2015;20(2):2208-28.", "FDA IND Safety Reporting requirements, 21 CFR 312.32.", "Global Ibogaine Therapist Alliance (GITA) Clinical Guidelines for Ibogaine-Assisted Detoxification. 2015.", "Cherian KN, et al. Exploratory open-label clinical trial of ibogaine for veterans with TBI and PTSD. Nature Medicine. 2024;30:1667–1673." ] }, { "slug": "who-is-a-good-candidate-for-ibogaine-treatment", "title": "Who Is a Good Candidate for Ibogaine Treatment?", "category": "safety", "categoryLabel": "Safety & Screening", "content_type": "article", "meta_description": "Learn who may benefit from ibogaine treatment, what medical screening involves, and which conditions make someone a poor candidate. Evidence-based overview.", "read_time": "7 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Noller GE, Frampton CM, Bhakta B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.", "Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.", "Mash DC, et al. Ibogaine in the Treatment of Heroin Withdrawal. Alkaloids Chem Biol. 2018;76:197-241.", "Ona G, et al. Ibogaine safety concerns in opioid use disorder treatment: A systematic review. J Psychopharmacol. 2023.", "Davis AK, et al. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020.", "MAPS. Observational Study of Ibogaine-Assisted Treatment for Opioid Use Disorder. ClinicalTrials.gov NCT02950610.", "FDA. Breakthrough Therapy Designation Request Background. 2021.", "Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.", "Meisner JA, et al. Ibogaine-associated cardiac arrest and death: case series and review of the literature. Ther Adv Psychopharmacol. 2016.", "Stanford RESTORE Program. Ibogaine and magnesium for veterans with TBI and PTSD. Nature Medicine. 2024." ] }, { "slug": "ibogaine-legal-status-panama", "title": "Ibogaine Legal Status in Panama", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Legal", "country_name": "Panama", "meta_description": "Panama has no federal scheduling of ibogaine, making it one of Latin America's most accessible destinations for legal ibogaine treatment. Last verified April 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Panama Law 23 of 1986, Que dicta medidas para la prevención de los delitos relacionados con drogas — https://www.asamblea.gob.pa/", "Ministerio de Salud de Panamá (MINSA), Dirección de Farmacia y Drogas — https://www.minsa.gob.pa/", "Global Drug Survey: Ibogaine International Legal Status Overview, 2024", "MAPS (Multidisciplinary Association for Psychedelic Studies), Ibogaine country policy tracker — https://maps.org/", "U.S. FDA, Breakthrough Therapy Designation for ibogaine in opioid use disorder — https://www.fda.gov/", "Asamblea Nacional de Panamá, legislative registry — https://www.asamblea.gob.pa/", "Noller GE, Frampton CM, Yazar-Klosinski B. 'Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.' American Journal of Drug and Alcohol Abuse, 2018." ], "flag_code": "pa" }, { "slug": "ibogaine-legal-status-belize", "title": "Ibogaine Legal Status in Belize", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Belize", "meta_description": "Ibogaine is unscheduled in Belize, creating a legal grey area. Learn about clinic access, recent developments, and risks. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Belize Misuse of Drugs Act, Chapter 103 of the Laws of Belize (Revised Edition 2020), Government of Belize", "United Nations Convention on Psychotropic Substances, 1971 — Schedule of Controlled Substances (ibogaine not listed)", "United Nations Office on Drugs and Crime (UNODC), Commentary on the Convention on Psychotropic Substances, 1971", "World Health Organization, Expert Committee on Drug Dependence (ECDD) — Reviews of ibogaine (36th, 40th, and 44th meetings; ibogaine not recommended for scheduling)", "U.S. Drug Enforcement Administration, Drug Scheduling: Ibogaine listed as Schedule I under 21 U.S.C. § 812", "Belizean National Assembly legislative records — no ibogaine-specific bills introduced as of April 2026 (searchable at www.nationalassembly.gov.bz)", "Belize Ministry of Health and Wellness — no ibogaine-specific advisories or guidelines published as of April 2026 (www.health.gov.bz)" ], "flag_code": "bz" }, { "slug": "ibogaine-legal-status-peru", "title": "Ibogaine Legal Status in Peru", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Peru", "meta_description": "Ibogaine is unscheduled in Peru, existing in a legal gray area. Learn about treatment access, clinics, recent developments, and risks. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Decreto Legislativo No. 824 — Ley de Lucha Contra el Tráfico Ilícito de Drogas (Peru, 1996): https://www.leyes.congreso.gob.pe/Documentos/DecretosLegislativos/00824.pdf", "DEVIDA — Comisión Nacional para el Desarrollo y Vida sin Drogas, controlled substances information: https://www.devida.gob.pe", "Instituto Nacional de Cultura (INC) Resolution No. 049-2008-INC, recognizing ayahuasca as national cultural heritage (Peru, 2008)", "Constitución Política del Perú, Article 89 — indigenous community rights: https://www.congreso.gob.pe/Docs/constitucion/", "United Nations Convention on Psychotropic Substances (1971) — Schedule of controlled substances (ibogaine not listed): https://www.unodc.org/unodc/en/treaties/psychotropics.html", "Ministerio de Salud del Perú (MINSA) — traditional medicine regulatory framework: https://www.gob.pe/minsa", "Ona, G. & Bouso, J.C. (2020). 'Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs.' Neuroscience & Biobehavioral Reviews — contextual reference on ibogaine pharmacology", "Global Ibogaine Therapist Alliance (GITA) — Provider standards and harm reduction guidelines: https://www.ibogainealliance.org" ], "flag_code": "pe" }, { "slug": "ibogaine-legal-status-democratic-republic-of-congo", "title": "Ibogaine Legal Status in DR Congo", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Democratic Republic of Congo", "meta_description": "Is ibogaine legal in the Democratic Republic of Congo? Current scheduling status, treatment centers, access methods, and legal developments. Last verified April 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Loi n° 18/030 du 13 décembre 2018 portant protection de la santé publique contre les méfaits de l'alcool et des substances psychoactives (Democratic Republic of Congo)", "United Nations Single Convention on Narcotic Drugs, 1961 — Schedule of Controlled Substances (ibogaine not listed): https://www.unodc.org/unodc/en/commissions/CND/conventions.html", "United Nations Convention on Psychotropic Substances, 1971 — Schedules I–IV (ibogaine not listed): https://www.unodc.org/unodc/en/commissions/CND/conventions.html", "United Nations Office on Drugs and Crime — Country Profile: Democratic Republic of the Congo: https://www.unodc.org/unodc/en/drug-trafficking/index.html", "Ministère de la Santé Publique, Hygiène et Prévention — République Démocratique du Congo: https://www.sante.gouv.cd/", "Gabon Decree recognizing Tabernanthe iboga as national heritage plant — Ministry of Forests, Environment and Protection of Nature, Gabon (referenced for regional context)", "Alper, K.R. (2001). Ibogaine: A Review. The Alkaloids: Chemistry and Biology, 56, 1–38 — pharmacology and cultural context reference", "MAPS (Multidisciplinary Association for Psychedelic Studies) — Ibogaine legal status overview: https://maps.org/ibogaine/", "Global Drug Survey — International drug policy monitoring data", "UN Commission on Narcotic Drugs (CND) — Session records on ibogaine scheduling considerations: https://www.unodc.org/unodc/en/commissions/CND/index.html" ], "flag_code": "cd" }, { "slug": "ibogaine-legal-status-cameroon", "title": "Ibogaine Legal Status in Cameroon", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Cameroon", "meta_description": "Ibogaine is unscheduled in Cameroon, where iboga holds deep traditional roots. Learn about legal status, treatment access, and recent developments. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Cameroon Law No. 97/019 of September 9, 1997 on the Control of Narcotic Drugs and Psychotropic Substances (République du Cameroun, Journal Officiel)", "United Nations Convention on Psychotropic Substances, 1971 — Schedule of Controlled Substances (UNODC): https://www.unodc.org/unodc/en/commissions/CND/conventions.html", "World Health Organization Expert Committee on Drug Dependence (ECDD) — Ibogaine Pre-Review Documentation: https://www.who.int/groups/expert-committee-on-drug-dependence", "UNODC World Drug Report — Central Africa Regional Overview: https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report.html", "Ministère de la Santé Publique du Cameroun — Politique Nationale de Médecine Traditionnelle: https://www.minsante.cm", "Economic Community of Central African States (ECCAS) — Regional Drug Policy Framework: https://www.ceeac-eccas.org", "Fernandez, J.W. (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press.", "Nze Nguema, F.P. (1995). Iboga et traditions religieuses en Afrique centrale. Cahiers d'études africaines.", "African Union Drug Control Programme — Continental Drug Control Policy Review (2023–2025): https://au.int", "Noller, G.E., Frampton, C.M., Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence: a systematic review. Journal of Psychedelic Studies. https://doi.org/10.1556/2054.01.2018.002" ], "flag_code": "cm" }, { "slug": "ibogaine-legal-status-senegal", "title": "Ibogaine Legal Status in Senegal", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Senegal", "meta_description": "Ibogaine is unscheduled in Senegal, where iboga holds deep cultural and religious roots. Last verified April 22, 2026. Learn about access, clinics, and risks.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Senegal Law No. 97-18 of February 1, 1997, on Narcotic Drugs and Psychotropic Substances (Loi n° 97-18 du 1er février 1997 portant Code des drogues et des stupéfiants)", "United Nations Convention on Psychotropic Substances, 1971 — Schedule of controlled substances (ibogaine not listed): https://www.unodc.org/unodc/en/commissions/CND/conventions.html", "United Nations Office on Drugs and Crime (UNODC) — Senegal country profile: https://www.unodc.org/westandcentralafrica/en/senegal.html", "Ordre National des Pharmaciens du Sénégal — regulatory overview: http://www.onps.sn/", "Nayak SM et al., 'Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports,' Pharmacopsychiatry, 2021 — ibogaine drug interaction context", "Cherian KN et al., 'Magnesium–ibogaine therapy in veterans with traumatic brain injuries,' Nature Medicine, 2024: https://www.nature.com/articles/s41591-023-02705-w", "UNESCO — Bwiti initiation rite of the Mitsogho communities (Gabon), recognized Intangible Cultural Heritage, 2008: https://ich.unesco.org/en/RL/bwiti-initiation-rite-of-the-mitsogho-communities-00197", "International Narcotics Control Board (INCB) — Annual Report 2023, West Africa regional overview: https://www.incb.org/incb/en/publications/annual-reports/annual-report-2023.html" ], "flag_code": "sn" }, { "slug": "ibogaine-legal-status-czech-republic", "title": "Ibogaine Legal Status in Czech Republic", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Czech Republic", "meta_description": "Ibogaine is unscheduled in the Czech Republic. Learn about current laws, treatment access, clinics, and recent legal developments. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "https://www.zakonyprolidi.cz/cs/1998-167 — Act No. 167/1998 Coll. on Addictive Substances (Czech Republic)", "https://www.zakonyprolidi.cz/cs/2010-467 — Government Regulation No. 467/2009 Coll. on personal possession thresholds", "https://www.sukl.cz/ — State Institute for Drug Control (SÚKL), Czech Republic", "https://www.emcdda.europa.eu/ — European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)", "https://www.druginfo.cz/ — Národní monitorovací středisko pro drogy a závislosti (Czech National Drug Monitoring Centre)", "https://www.mzcr.cz/ — Czech Ministry of Health", "https://www.emcdda.europa.eu/publications/drug-profiles/ibogaine_en — EMCDDA Drug Profile: Ibogaine" ], "flag_code": "cz" }, { "slug": "ibogaine-legal-status-uruguay", "title": "Ibogaine Legal Status in Uruguay", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Uruguay", "meta_description": "Ibogaine is unscheduled in Uruguay, meaning it is not explicitly controlled. Learn about clinic access, legal context, and recent developments. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Uruguay Law 14.294 — Ley de Estupefacientes (1974, as amended): https://www.impo.com.uy/bases/leyes/14294-1974", "Uruguay Decree 286/000 — Reglamentación de estupefacientes y sustancias psicotrópicas: https://www.impo.com.uy/bases/decretos/286-2000", "Uruguay Law 19.172 — Regulación y Control del Cannabis (2013): https://www.impo.com.uy/bases/leyes/19172-2013", "Junta Nacional de Drogas (JND) — Uruguay: https://www.gub.uy/junta-nacional-drogas/", "Ministerio de Salud Pública del Uruguay: https://www.gub.uy/ministerio-salud-publica/", "United Nations 1971 Convention on Psychotropic Substances — Schedule of Substances: https://www.unodc.org/unodc/en/commissions/CND/conventions.html", "Cherian KN et al. (2024). Ibogaine with magnesium for traumatic brain injury: A randomized, controlled trial. Nature Medicine. https://www.nature.com/articles/s41591-024-02883-1", "MAPS — Ibogaine Research Overview: https://maps.org/ibogaine/", "Global Drug Survey — Uruguay Drug Policy Profile: https://www.globaldrugsurvey.com" ], "flag_code": "uy" }, { "slug": "ibogaine-legal-status-ireland", "title": "Ibogaine Legal Status in Ireland", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Ireland", "meta_description": "Ibogaine is a controlled substance in Ireland under the Misuse of Drugs Act. Learn about scheduling, clinics, access, and recent legal developments.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Misuse of Drugs Act 1977 (Ireland): https://www.irishstatutebook.ie/eli/1977/act/12/enacted/en/html", "Misuse of Drugs Act 1984 (Ireland): https://www.irishstatutebook.ie/eli/1984/act/18/enacted/en/html", "Misuse of Drugs Regulations 2017, S.I. No. 173 of 2017: https://www.irishstatutebook.ie/eli/2017/si/173/made/en/print", "Criminal Justice Act 1999 (Ireland) — mandatory minimum sentences for drug trafficking: https://www.irishstatutebook.ie/eli/1999/act/10/enacted/en/html", "Health Products Regulatory Authority (HPRA) — controlled drugs information: https://www.hpra.ie/homepage/medicines/special-topics/controlled-drugs", "Citizens' Assembly on Drug Use — Final Report 2023: https://www.citizensassembly.ie/previous-assemblies/citizens-assembly-on-drug-use/reports-and-recommendations/", "HSE Drug and Alcohol Helpline: https://www.hse.ie/eng/services/list/5/addiction/drugalcohol/", "Ana Liffey Drug Project (harm reduction, Ireland): https://www.aldp.ie/" ], "flag_code": "ie" }, { "slug": "ibogaine-legal-status-italy", "title": "Ibogaine Legal Status in Italy", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Illegal", "country_name": "Italy", "meta_description": "Ibogaine is a controlled substance in Italy. Learn about current laws, treatment access, recent developments, and risks. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Decreto del Presidente della Repubblica n. 309 del 9 ottobre 1990, Testo Unico sugli stupefacenti e sostanze psicotrope — https://www.normattiva.it/uri-res/N2Ls?urn:nir:stato:decreto.del.presidente.della.repubblica:1990-10-09;309", "Ministero della Salute — Tabelle delle sostanze stupefacenti e psicotrope — https://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=4574&area=stupefacenti&menu=vuoto", "Agenzia Italiana del Farmaco (AIFA) — Regulatory framework for controlled substances — https://www.aifa.gov.it", "EU Clinical Trials Register (EUCTR) — Search for ibogaine trials — https://www.clinicaltrialsregister.eu", "ClinicalTrials.gov — Ibogaine studies registry — https://clinicaltrials.gov/search?term=ibogaine", "European Union Drugs Agency (EUDA, formerly EMCDDA) — Drug policy profiles: Italy — https://www.emcdda.europa.eu/countries/drug-reports/2024/italy_en", "Forum Droghe — Italian drug policy reform advocacy — https://www.forumDroghe.org", "Novaes Colugnati et al., 'Ibogaine and addiction in the animal kingdom: A systematic review,' Substance Abuse Treatment, Prevention, and Policy (2017) — for pharmacological background", "Koenig & Hilber, 'The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relationship,' Molecules (2015) — https://doi.org/10.3390/molecules20022208" ], "flag_code": "it" }, { "slug": "ibogaine-legal-status-argentina", "title": "Ibogaine Legal Status in Argentina", "category": "legality", "categoryLabel": "Legality & Access", "content_type": "country_page", "legal_status": "Unscheduled", "country_name": "Argentina", "meta_description": "Argentina does not schedule ibogaine federally. Learn about clinics, access methods, recent developments, and risks. Last verified April 22, 2026.", "read_time": "5 min read", "publish_date": "2026-04-22", "last_updated": "2026-04-22", "published": true, "tweeted": false, "fb_posted": false, "threaded": false, "fb_threaded": false, "sources": [ "Argentina Law 23.737 – Narcotic Drugs and Psychotropic Substances Act (1989): https://servicios.infoleg.gob.ar/infolegInternet/anexos/0-4999/138/texact.htm", "ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) – Controlled Substances Database: https://www.argentina.gob.ar/anmat", "UN Convention on Psychotropic Substances (1971) – Schedule I–IV lists, to which Argentina is a signatory: https://www.unodc.org/unodc/en/treaties/psychotropics.html", "Argentine Chamber of Deputies – Legislative tracking for psychedelic therapy proposals (2024–2025): https://www.hcdn.gob.ar", "MAPS (Multidisciplinary Association for Psychedelic Studies) – Global ibogaine policy overview: https://maps.org/ibogaine", "Global Ibogaine Therapist Alliance (GITA) – Provider standards and country status reports: https://www.ibogainealliance.org" ], "flag_code": "ar" } ]